Review

# RNA-binding proteins, neural development and the addictions

## C. D. Bryant* and N. Yazdani

*Laboratory of Addiction Genetics, Department of Pharmacology and Experimental Therapeutics and Psychiatry, Boston University School of Medicine, Boston, MA, USA*
*\*Corresponding author: C. D. Bryant, Laboratory of Addiction Genetics, Department of Pharmacology and Experimental Therapeutics and Psychiatry, Boston University School of Medicine, 72 E. Concord St., L-606C, Boston, MA 02118, USA. E-mail: camron@bu.edu*

**Transcriptional and post-transcriptional regulation of gene expression defines the neurobiological mechanisms that bridge genetic and environmental risk factors with neurobehavioral dysfunction underlying the addictions. More than 1000 genes in the eukaryotic genome code for multifunctional RNA-binding proteins (RBPs) that can regulate all levels of RNA biogenesis. More than 50% of these RBPs are expressed in the brain where they regulate alternative splicing, transport, localization, stability and translation of RNAs during development and adulthood. Dysfunction of RBPs can exert global effects on their targetomes that underlie neurodegenerative disorders such as Alzheimer's and Parkinson's diseases as well as neurodevelopmental disorders, including autism and schizophrenia. Here, we consider the evidence that RBPs influence key molecular targets, neurodevelopment, synaptic plasticity and neurobehavioral dysfunction underlying the addictions. Increasingly well-powered genome-wide association studies in humans and mammalian model organisms combined with ever more precise transcriptomic and proteomic approaches will continue to uncover novel and possibly selective roles for RBPs in the addictions. Key challenges include identifying the biological functions of the dynamic RBP targetomes from specific cell types throughout subcellular space (e.g. the nuclear spliceome vs. the synaptic translatome) and time and manipulating RBP programs through post-transcriptional modifications to prevent or reverse aberrant neurodevelopment and plasticity underlying the addictions.**

RNA-binding proteins (RBPs) bind both RNAs and proteins to regulate all aspects of mRNA biogenesis and metabolism, 'from the cradle (transcription) to the grave (decay)' (Doyle & Kiebler 2012). They bind and package specific pre-mRNAs and proteins into unique and highly dynamic ribonucleoprotein (RNP) complexes to regulate splicing, editing, polyadenylation, nuclear export, localization, translation and stability (Glisovic *et al.* 2008). More than 1000 mammalian genes code for RBPs and 20% of all protein products represent RBPs (Gerstberger *et al.* 2014), reflecting the extensive splicing and diversity of RBP function. RNA-binding proteins possess modular RNA-binding motifs that cooperatively determine target specificity as well as auxiliary domains that mediate protein–protein interactions and post-translational modifications that can modify RNA binding, transport and localization of RBPs (Glisovic *et al.* 2008). Importantly, post-translational modification of RBP signaling is potentially a useful strategy to prevent and treat a variety of disease states (Kim *et al.* 2014; Wang *et al.* 2009).

Dozens of RBPs have established roles in neurodevelopment and synaptic plasticity (Doxakis 2014) and a large literature documents the contribution of RBPs to neurodegenerative disorders (Romano & Buratti 2013) and neurodevelopmental disorders such as autism and schizophrenia (Bill *et al.* 2013; Fernandez *et al.* 2013). However, much less is known regarding RBPs and neuropsychiatric disorders such as the addictions. There are several reasons to suspect that RBPs play a crucial role in the addictions. First, alternative splicing – one of the key nuclear functions of RBPs – is highly prevalent within the central nervous system (CNS) and is associated with several psychiatric disorders (Glatt *et al.* 2011). Human genome-wide association studies (GWAS) have yet to uncover statistically significant associations between RBPs and the addictions; however, several genome-wide significant intronic variants for psychiatric disorders have been identified within RBP targets that affect RBP binding and splicing (Glatt *et al.* 2011). Second, several RBPs play a critical role in neurodevelopment and, thus, could mediate transcriptomic programs that are activated following encounter with stressors during critical developmental periods and increase risk for the addictions (Andersen & Teicher 2009). Third, drug-induced synaptic plasticity is an important component throughout all stages of addiction, and dozens of RBPs have been identified that exhibit cytoplasmic function in transporting, localizing and translating mRNAs in synaptic plasticity (Thomas *et al.* 2014; Tolino *et al.* 2012).

## Considering the addictions as neuropsychiatric disorders that have a neurodevelopmental component

Genetic and fluctuating environmental risk factors affect neurodevelopment and the later neurobiological responses to external stimuli (van Loo & Martens 2007). The addictions are gene × environment (G × E) disorders that require drug exposure to manifest. Both genetic and environmental risk factors likely interact to affect neurodevelopment and neuropharmacological sensitivity to reinforcing stimuli, including drugs and associated cues (Andersen & Teicher 2009; Leyton & Vezina 2014). Severe childhood adversity is a key environmental risk factor that greatly increases susceptibility to the addictions (Kendler *et al.* 2000) and early-life stress causes structural changes that affect mesolimbic reward function, including reduced hippocampal and prefrontal cortical development that may heighten dopamine release in the nucleus accumbens (Andersen & Teicher 2009). We posit that a subset of RBPs orchestrate neurodevelopmental plasticity induced by environmental risk factors that increases susceptibility to the addictions. The mesocorticolimbic dopaminergic circuitry is involved in reward/aversion processing and positive/negative reinforcement learning in the addictions and includes midbrain dopaminergic neuron projections from the ventral tegmental area to the medial prefrontal cortex and nucleus accumbens and glutamatergic projections from the prefrontal cortex to the nucleus accumbens (Volman *et al.* 2013). Mesocorticolimbic dysfunction is common in numerous neurodevelopmental and neuropsychiatric disorders, especially the addictions (Dichter *et al.* 2012). Understanding the potential contribution of RBPs in mesocorticolimbic development, environmental risk factor-induced plasticity and drug-induced plasticity could improve our understanding of the heritable basis of addictive disorders, especially within the context of G × E interactions (Wermter *et al.* 2010).

As an example of a hypothesized role for RBPs in G × E interactions in neurodevelopment and plasticity underlying psychiatric traits, a genetic variant in the gene coding for brain-derived neurotrophic factor (BDNF; the Val66/Met allele) that decreases activity-dependent secretion of BDNF is associated with phenotypic variation in psychiatric endophenotypes (e.g. fear/aversion learning) during childhood vs. adolescence (Casey *et al.* 2009). Furthermore, individuals carrying the Val66/Met BDNF variant that also underwent early childhood adversity (institutionalization) showed a decrease in cortical volume, an increase in amygdala volume, an increase in behavioral anxiety and an increase in cortisol stress response (Casey *et al.* 2009). Accumulating evidence indicates that RBPs can regulate translation of BDNF (Allen *et al.* 2013; Vanevski & Xu 2015) and that an increase in BDNF signaling can increase translation and synaptic localization of RBPs (Castren *et al.* 2002). In this review, we summarize recent examples of RBPs that affect primary molecular targets and cellular, neurodevelopmental and neurobehavioral functions relevant to the addictions (Table 1). We begin by discussing examples that contain the most direct experimental and circumstantial evidence that draws a link to the addictions [fragile X mental retardation

protein (FMRP) and heterogeneous nuclear ribonucleoproteins (hnRNPs)]. Toward the end, we discuss those RBPs for which there is less, yet accumulating evidence [RNA-binding protein, fox-1 homolog (RBFOX) and CUG-BP, ELAV-like factor (CELF) proteins]. Finally, we include a section on RNA editing and the addictions, as this exciting new area of research comprises distinct molecular mechanisms from the remainder of the review. Because multiple RBPs frequently coordinate in large RNP complexes to coordinate post-transcriptional regulation of mRNAs, we have attempted to draw links between various discussed RBPs and their families whenever relevant, while keeping in mind that it would be beyond the scope of the review to document all possible connections between the large number of RBPs that are discussed.

## FMRP

Fragile X mental retardation protein (FMRP) is a polyribosome-associated neuronal RBP that targets and translationally represses mRNAs associated with synaptic plasticity and has been implicated in autism, affective disorders, attention-deficit hyperactivity disorder, bipolar disorder, schizophrenia and the addictions (Fernandez *et al.* 2013; Smith *et al.* 2014). It is expressed throughout neurodevelopment and is necessary for proper differentiation, migration, axon formation, refinement and stabilization, synapse formation and circuit wiring of neocortical layers (Till 2010). It inhibits ribosomal translocation of mRNAs that is relieved following activity-dependent signaling to permit cytoskeletal remodeling that underlies synaptic plasticity (Darnell & Klann 2013; Darnell *et al.* 2011). The N-terminal region contains two Tudor domains that bind non-coding RNAs followed by a nuclear localization signal (NLS). The middle of the protein contains two hnRNP K homology (KH) domains that further specify RNA and protein interactions. The C-terminal region contains a nuclear export signal (NES) followed by an RGG box that directly binds to mRNA targets (Fernandez *et al.* 2013).

Signaling by several different receptor types modulates FMRP activity, including mGluRs, AMPA, GABA, NMDA, TrkB, dopamine and cannabinoid receptors (Fernandez *et al.* 2013). Accordingly, FMRP targets hundreds of neurodevelopmental and neuroplasticity proteins involved in cytoskeletal remodeling; many of these targets have been associated with the addictions, including mGluR1, mGluR5, PSD-95, CYFIP1/2, GABA-A receptor subunits, NR2A/2B NMDA receptor subunits, Homer1, neuroligins, CREB-binding protein and D1 dopamine receptor-coupled GRK2 (Darnell & Klann 2013; Wang *et al.* 2008). The FMRP also targets elongation factor-1 and -2 (EF-1, EF-2), argonaute 1/2 (Ago1/2) and Dicer, which are ubiquitously involved in protein translation and miRNA processing, respectively (Darnell & Klann 2013). Thus, FMRP can also exert widespread, indirect regulation of the translatome.

With regard to drugs of abuse, deletion of FMRP perturbs midbrain dopaminergic neuron development, amphetamine-induced dopamine release in the striatum and

**Table 1:** RBPs associated with the addictions

| RBP | Addiction-relevant targets | RNA function | Neurodevelopment, neuroplastic function | Addiction-relevant circuitry | Addiction-associated result | References |
|---|---|---|---|---|---|---|
| ADAR1/2 | 5-HT2C receptor, AMPA receptor, GABA-A receptor | RNA editing, pri-miRNA binding and miRNA biogenesis | Neural differentiation and induction | Ubiquitous expression, hypothalamus, striatum, mesocorticolimbic circuitry, dorsal raphe nucleus, forebrain, cortex, hippocampus, diencephalon | Overeating, motivation to eat in a competing reward environment, novelty-induced locomotor activity, alcohol drinking, cocaine abstinence and seeking, nicotine withdrawal | (Akubuiro et al. 2013; Dracheva et al. 2009; Satterlee et al. 2014; Schmidt et al. 2014; Watanabe et al. 2014; Zaniewska et al. 2015) |
| CELF4 | NMDA receptors, MAPT | Splicing, 3′ UTR binding and mRNA stability, translation, localization | Neuronal differentiation and excitation, corticothalamic development, synaptic transmission and function, predicted synaptic plasticity | Ubiquitous expression, hippocampus, cortex | Amphetamine response in humans, hyperactivity, hyperphagia-associated obesity, food-related obsessions | (Comuzzie et al. 2012; Halgren et al. 2012; Hart et al. 2012) |
| CELF6 | Serotonergic neurons, MAPT | Splice enhancement and repression | Expressed during neurodevelopment, beginning at E14 | Basal forebrain, ventral tegmental area, locus coeruleus, prefrontal and hippocampal cortices, hypothalamus | Cocaine-conditioned reward | (Dougherty 2015; Dougherty et al. 2013; Maloney et al. 2015) |
| ELAVL | cfos, BDNF, GAP-43, Nova1, GABA-A receptor, glycine alpha-2 receptor | Splicing, 3′ UTR binding, translation, polyadenylation, stability, protein synthesis, transport | Neuronal differentiation, maintenance, maturation, axon growth, dendritogenesis, synaptic plasticity | Neocortex, hippocampus | Cocaine-induced changes in expression and phosphorylation | (Pascale et al. 2011; Tiruchinapalli et al. 2008) |
| FMRP | Cyfip1/2, AMPA receptor, mGluR1, mGluR5, ADAR, PSD-95, Homer1, CREB BP, GRK2 | Transport, translational repression via stalling of ribosomal translocation, stability | Cell fate, progenitor maintenance, neurite, axonal and dendritic outgrowth, glutamate receptor trafficking, dendritic spine morphology | Mesocorticolimbic circuitry, hippocampus | Cocaine and amphetamine neurobehavioral plasticity, synaptic and structural plasticity | (Bhogal et al. 2011; Fish et al. 2013; Fulks et al. 2010; Kumar et al. 2013; Pilaz & Silver 2015; Smith et al. 2014) |
| HNRNPA1 | NMDA receptors | Splicing, spliceosome, translation, export, stability | Neurogenesis | Ubiquitous expression | Opioid and psychostimulant-induced changes in expression; co-regulated with Nurr1 | (Johnson et al. 2011; Wang et al. 2011) |

**Table 1:** Continued

| RBP | Addiction-relevant targets | RNA function | Neurodevelopment, neuroplastic function | Addiction-relevant circuitry | Addiction-associated result | References |
|---|---|---|---|---|---|---|
| HNRNPH1 | OPRM1, RBFOX, NMDA receptor, Per2 | Splicing, regulation of splicing activity, polyadenylation and cleavage, 5' UTR translational suppression | Unknown | Ubiquitous expression | Heroin addiction, MOR splicing, methamphetamine stimulant response, association with Nurr1 expression | (Johnson et al. 2011; Song et al. 2012; Xu et al. 2014; Yazdani et al. 2015) |
| HNRNPH2 | | Splicing | Unknown | Low expression | Opioid and psychostimulant-induced change in expression | (Wang et al. 2011) |
| HNRNPK | TH, MOR, SERT, neuronal nicotinic acetylcholine receptor beta2 | Transcription, silencing, splicing, 3' UTR binding and stability, translation | Hippocampal synaptic plasticity, dendritic spine morphology, filopodia formation, synapse maturation, axon development | Mesocorticolimbic circuitry, hippocampus, ventral midbrain | Activates TH and MOR transcription, promotes SERT translation, activates transcription of beta2 subunit of the neuronal nicotinic acetylcholine receptor | (Banerjee et al. 2014; Choi et al. 2008; Du et al. 1998) |
| HNRNPM1 | D2 dopamine receptor | Unknown | Unknown | Unknown | Splicing of D2 dopamine receptor | (Park et al. 2011) |
| Nova1/2 | D2 dopamine receptor, GABA-A and GABA-B receptors, NMDA receptor, nicotinic acetylcholine receptor, GIRK2 | Repression of splicing, polyadenylation | Synaptogenesis, neuronal migration of cortical and purkinje neurons, neuronal inhibition | Neocortex and midbrain (Nova1), hindbrain, motoneurons and ventral spinal cord (Nova2) | Splicing of D2 dopamine receptor | (Park et al. 2011) |
| PCBP 1–4 (HNRNPE1–4) | Tyrosine hydroxylase, MOR | Transcription, 3' UTR binding and stability, translational co-activation and repression | Corticogenesis, axonogenesis | TH-positive cells of the midbrain, locus coeruleus | Nicotine-induced changes in TH mRNA | (Boschi et al. 2015; Choi et al. 2007, 2008, 2009; Pilaz & Silver 2015) |
| PTBP1–2 (HNRNPI) | D2 dopamine receptor, ΔfosB, PSD-95, PTBP, GABA-A receptor, Grip1, glycine receptor alpha2 | Splicing, polyadenylation, nonsense-mediated decay, transport, stability, translation initiation | Neuronal differentiation, synapse maturation and stability, plasticity | Cortex, hippocampus | D2 dopamine receptor splicing | (Sasabe et al. 2011) |
| RBFOX1 (A2BP1) | Cell adhesion molecules, HNRNPH1, PACAP receptor, GABA-A receptor, NMDA receptor, Grip1, Csnk1d, PTBP | Splicing, 3' UTR binding and stability, polyadenylation | Transmission, membrane excitability | Ubiquitous, basal forebrain, neocortex, hippocampus, nucleus accumbens | Cocaine-conditioned reward, nicotine and alcohol dependence | (Feng et al. 2014; Fogel et al. 2012; Zhong et al. 2015) |

**Table 1:** Continued

| RBP | Addiction-relevant targets | RNA function | Neurodevelopment, neuroplastic function | Addiction-relevant circuitry | Addiction-associated result | References |
|---|---|---|---|---|---|---|
| Tra2β | RGS4, glutamate receptors | Splicing | Neuronal survival, differentiation, cortical neurogenesis | Locus coeruleus, cerebral cortex | Morphine-induced splicing of RGS4; DARPP-32 induces splicing of Tra2β | (Benderska et al. 2010; Li et al. 2013) |
| ZBP1 | B-actin, GAP-43, Homer1, many other predicted targets | 3' UTR binding and stability, translational repression, axonal mRNA transport and localization | Axon guidance, outgrowth and branching, dendritic development and morphology, hippocampal development and plasticity, corticogenesis, axonogenesis, synaptogenesis, regeneration | Ubiquitous expression, forebrain, hippocampus | Cocaine-conditioned reward, methamphetamine stimulant response | (Bryant et al. 2012; Lapidus et al. 2012) |

prefrontal cortex, psychostimulant-induced locomotor activity, stereotypy and drug reward (Fish et al. 2013; Fulks et al. 2010). The FMRP deletion also disrupts cocaine-induced neurobehavioral plasticity in the nucleus accumbens, including decreased locomotor sensitization, enhanced stereotypy, perturbed dendritic morphology, changes in AMPA/NMDA receptor ratios and glutamatergic transmission and reduced cocaine reward that is associated with increased mGluR5 activation (Smith et al. 2014). In prefrontal cortical neurons, D1 dopamine receptor activation is sufficient to induce FMRP phosphorylation and synthesis of synaptic proteins involved in glutamate receptor trafficking and plasticity (Wang et al. 2008, 2010). In another example that indirectly implicates FMRP in the addictions, cytoplasmic FMRP-interacting protein 1 (CYFIP1) inhibits elf4E-mediated cap-dependent mRNA translation of proteins involved in actin cytoskeleton remodeling and dendritic spine maturation (De Rubeis et al. 2013; Napoli et al. 2008) and mutations in the closely related Cyfip2 gene in mice modulate psychostimulant-induced locomotor activity and sensitization, dendritic morphology and AMPA receptor neurotransmission (Kumar et al. 2013). In addition to an mGluR5 mechanisms underlying neurobehavioral dysfunction in the absence of FMRP (Bear et al. 2004; Smith et al. 2014), neuronal activity and BDNF/TrkB signaling can regulate expression of FMRP in the hippocampus (Castren et al. 2002) and FMRP deletion perturbs both BDNF and TrkB spatiotemporal expression and signaling in neurodevelopment and neuroplasticity (Castren & Castren 2014). Thus, both BDNF/TrkB and mGluR5 signaling could converge on FMRP mechanisms of psychostimulant neurobehavioral plasticity (Kumar et al. 2013; Smith et al. 2014).

Because FMRP deletion increases protein translation and disrupts structural and synaptic plasticity induced by glutamate receptor signaling (e.g. mGluR-LTD), an important question is whether or not fine-tuning glutamatergic signaling by the use of pharmaceuticals targeting NMDA receptors and mGluR can improve the outcome of neurodevelopmental and neuropsychiatric disorders associated with FMRP dysfunction (Bear et al. 2004; Michalon et al. 2012), including the addictions (Cleva et al. 2010). The FMRP also undergoes post-translational modifications, including mGluR-mediated dephosphorylation and relief from translational repression as well as mTOR-mediated dephosphorylation by protein phosphatase 2A (PP2A) and re-establishment of translational repression via PP2A suppression (Ceman et al. 2003; Narayanan et al. 2008), presenting additional opportunities for perturbing FMRP mechanisms of neurodevelopmental and neuropsychiatric dysfunction.

## hnRNPs

Heterogeneous nuclear ribonucleoproteins (hnRNPs) are a large and diverse group of nucleoplasmic-localized multifunctional RBPs that form RNP complexes and can regulate splicing, export, localization, translation and stability (Dreyfuss et al. 2002; Han et al. 2010). Rapidly accumulating studies are identifying new contributions of hnRNPs to neurodevelopment (Liu & Szaro 2011; Sinnamon et al. 2012)

and synaptic plasticity (Folci *et al.* 2014; Leal *et al.* 2014; Sinnamon & Czaplinski 2011; Zhang *et al.* 2012). Heterogeneous nuclear ribonucleoproteins contain highly conserved, modular RNA recognition motifs (RRMs) that determine sequence binding specificity and affinity and intervening regions that localize and permit generalized and specific roles in post-transcriptional processing. The hnRNPs were originally classified based on their co-immunopurification in RNA complexes with monoclonal antibodies against the founding member hnRNP C, thus identifying hnRNP A-U (Dreyfuss *et al.* 1993). Although hnRNPs can be highly similar in protein structure and function, their nomenclature is not consistent with their sequence homology, suggesting independent evolution and expansion of several RRMs. As examples, some hnRNPs share greater sequence similarity with other RBP classes such as hnRNP A1 vs. ELAVL4/CELF1 or hnRNP C vs. the SR protein transformer-2$\beta$ (Tra2$\beta$) (Tang *et al.* 2012). Furthermore, other hnRNPs such as E/K, I/L, U, I (PTBP1) and hnRNP F/H contain separate, quasi-RRMs that do not share sequence homology with canonical RRMs of hnRNPs (Tang *et al.* 2012). Thus, discussing hnRNPs as a separate class is somewhat arbitrary but for ease of reference, here we will discuss addiction-relevant RBPs that have been named hnRNPs and in the immediately following sections, we will discuss hnRNPs that have alias names.

The mu opioid receptor (MOR) is a primary molecular target for the addictive properties of opioids and other drugs of abuse (Contet *et al.* 2004) and undergoes alternative splicing by hnRNP H1 binding to the intronic AGGG sequence and recruiting hnRNP A1, A2B1, AB, C, H3 and U, which results in exclusion of exon 2 and decreased expression of *Oprm1* (mu opioid receptor; MOR) (Xu *et al.* 2014). The MOR intronic SNP rs9479757 decreased binding of hnRNP H1, resulting in exon 2 skipping and increased MOR expression that was associated with increased severity of heroin dependence (Xu *et al.* 2014). hnRNP H1 and hnRNP F can also post-transcriptionally regulate MOR expression by repressing translation at the 5′ UTR (Song *et al.* 2012), providing a second level of MOR regulation by hnRNP H1.

We used fine-scale gene mapping with interval-specific congenic mouse lines to identify a 206-kb region on chromosome 11 containing *Hnrnph1* (the gene coding for hnRNP H1) and *Rufy1* that was necessary for reduced sensitivity methamphetamine-induced locomotor activity. Replicate mouse lines harboring transcription activator-like effector nucleases (TALENs)-induced frameshift deletions in *Hnrnph1* recapitulated the quantitative trait locus (QTL) phenotype, thus identifying *Hnrnph1* as the quantitative trait gene (Yazdani *et al.* 2015). Inheritance of this QTL caused a decrease in expression of *Bdnf*, *Elavl2*, *Elavl4* and *Nurr1* (nuclear receptor-related 1 protein) (Yazdani *et al.* 2015), a transcription factor that is crucial for the development and function of midbrain dopaminergic neurons (Campos-Melo *et al.* 2013). hnRNP H1 (along with hnRNP A1, K and M) has been shown to be co-regulated with *Nurr1* expression across neuronal cell lines (Johnson *et al.* 2011) and a recent review of proteomic studies of neuronal and brain expression with drugs of abuse identified psychostimulant- and opioid-induced changes in hnRNP H2 and A1 expression that could regulate gene networks enriched for protein modification/degradation,

synaptic/neuronal function, transmission and signaling (Wang *et al.* 2011). We are currently evaluating the potential role of *Hnrnph1* in the rewarding and reinforcing properties of psychostimulants and opioids and changes in the transcriptome and spliceome associated with *Hnrnph1* dysfunction.

*Hnrnph1* is highly and ubiquitously expressed throughout the mouse brain (Lein *et al.* 2007). It contains three quasi-RRMs that mediate binding to poly-(G) tracts to either enhance or silence splicing (Han *et al.* 2010). hnRNP H protein is primarily localized to the nucleus in primary rat cortical neurons and depolarization via KCl application increased the intensity of nuclear immunocytochemical staining (Fig. 1), suggesting activity-dependent nuclear function that is consistent with its role in alternative splicing and polyadenylation (Katz *et al.* 2010). Nevertheless, hnRNP H1 also contains three, intervening glycine-rich domains and the central domain contains an NLS that permits bidirectional transport between the nucleus and cytoplasm (Van Dusen *et al.* 2010). These modular glycine-rich domains are also necessary for regulation of splicing (Wang *et al.* 2012) and likely mediate interaction with other proteins, including complexing and cooperating with hnRNP A1, RBFOX2 and hnRNP F to enhance or suppress exon inclusion (Fisette *et al.* 2010; Mauger *et al.* 2008). hnRNP H1 can also cooperate with hnRNP I (see PCBP-1 below) to form a splicer enhancer complex in neurons (Chou *et al.* 1999).

To summarize, increasing evidence indicates that hnRNPs such as hnRNP H1 may be involved in establishing multiple addictions. The role of hnRNP H1 in activity-dependent synaptic plasticity is not known although intriguingly, *Hnrnph1* was identified as one of the most significantly upregulated transcripts in transcriptome analysis of cortical brain tissue following experimental traumatic brain injury (Kobori *et al.* 2002), which could indicate a role in regenerative plasticity. Available evidence from our laboratory indicates that neuronal stimulation induces an increase in hnRNP H staining that is localized to the nucleus (Fig. 1), suggesting that the contribution of hnRNP H1 to neuroplasticity is either indirect (e.g. via nuclear splicing or nuclear polyadenylation of synaptic targets) or that dendritic localization of hnRNP H requires signaling through specific receptors. We are currently testing the latter hypothesis in the context of the addictions by treating neurons with dopamine receptor agonists and examining changes in hnRNP H staining. Because hnRNP H1 can undergo several post-translational modifications such as phosphorylation, methylation and sumoylation (Chaudhury *et al.* 2010), there is potential to fine-tune hnRNP H1 signaling to prevent or normalize plasticity associated with the addictions.

## PCBPs (including hnRNP K)

Polycytosine-binding proteins (PCBPs) 1–4 (hnRNP E1–E4) and hnRNP K bind with high affinity to poly(C) DNA and RNA sequences to regulate transcription and post-transcriptional processing via three, modular hnRNP KH RNA-binding domains (Han *et al.* 2010). They also contain an intervening sequence between the second and third KH domains with

**Figure 1: Immunocytochemical staining of hnRNP H in rat cortical neurons following KCl-induced depolarization.** (a) Primary neocortical neurons were dissected from E18 Sprague-Dawley rat embryos (Charles River Laboratories, Newton, MA). Dissociated neurons were cultured neurons for 1 week. For the control, no treatment (No Tx) group, 1 ml of conditioned media was replaced with 1 ml of neurobasal media. For the 1-h and 2-h Tx groups, 1 ml of conditioned media was replaced with 1 ml of 20 mM KCl-enriched neurobasal media. Treated neurons were then washed, fixed, permeabilized, blocked and incubated with primary hnRNP H antibody (1:500 rabbit polyclonal, Bethyl Labs Montgomery, TX) in 1% bovine serum albumin (BSA) overnight at 4°C. Twelve hours later, neurons were washed and incubated with an Alexa Fluor 594 antibody (1:500 donkey anti-rabbit, Life Technologies, Carlsbad, CA) in 1% BSA. Processed coverslips were then stained with DAPI (blue) and mounted onto glass slides. Images were collected using a Zeiss AxioObserver microscope (Carl Zeiss Inc., Jena, Germany) under uniform settings for all three groups. Twenty serial images (frames) were captured per condition and fluorescence was quantified using ImageJ 1.49 under a uniform threshold range. Note both an increase in the number of H1-stained neurons following 1–2 h of KCl Tx as well as an increase in the fluorescent staining intensity after KCl treatment. (b) Semiquantification of fluorescence staining intensity. One-way ANOVA indicated a main effect of genotype ($F_{2,57} = 8.4$; $P = 0.0006$). *$P = 0.01$; **$P < 0.001$ (unpaired $t$-tests vs. No Tx).

NLSs (PCBP1 and 2) or an hnRNP K-specific nuclear shuttling domain to permit bidirectional transport. hnRNP K also has a SH-3 (KI)-binding domain and both hnRNP K and PCBP4 contain an NLS in the third KH domain (Choi *et al.* 2009). hnRNP K, PCBP1 and PCBP2 are located primarily in the nucleus whereas PCBP3 and 4 are located primarily in the cytoplasm (Chaudhury *et al.* 2010).

In neurodevelopment, PCBPs regulate axonogenesis (Thyagarajan & Szaro 2004) and corticogenesis (Pilaz & Silver 2015). PCBP1–3 are expressed in the adrenal medulla, midbrain and locus coeruleus, respectively, where they bind the 3′ UTR of tyrosine hydroxylase (TH, the enzyme necessary for synthesis of dopamine and norepinephrine) in the cytoplasm to increase stability and protein translation (Boschi *et al.* 2015; Czyzyk-Krzeska & Beresh 1996). In addition to regulating catecholamine synthesis, hnRNP K, PCBP1 and PCBP2 can all bind to the MOR promoter to activate MOR transcription whereas PCBP3 acts as a transcriptional repressor (Choi *et al.* 2007, 2008, 2009).

hnRNP K interacts with ELAVL2 to control neuronal differentiation (Yano *et al.* 2005) and regulates axonogenesis via post-transcriptional interaction with genes involved in neurodevelopment, transport, localization and cytoskeleton, including GAP-43 (Liu & Szaro 2011; Liu *et al.* 2008). hnRNP K exhibits early developmental expression in several components of the mesocorticolimbic circuitry and subsequently a more restricted expression to the hippocampus (Blanchette *et al.* 2006). hnRNP K can bind to the TH promoter to activate transcription (Banerjee *et al.* 2014) and co-localizes with TH in the ventral midbrain. Thus, hnRNP K could regulate catecholamine synthesis during midbrain dopaminergic neuron development, maintenance and synaptic plasticity in adulthood (Folci *et al.* 2014). hnRNPK also binds to the polyadenylation sequence within the 3′ UTR of the serotonin transporter (SERT), a primary molecular target for cocaine reward (Sora *et al.* 2001), to increase SERT protein levels by preventing miR-16-mediated inhibition of translation (Yoon *et al.* 2013). In addition to its link to catecholamines and monoamines, hnRNP K can bind to the MOR promoter and to the promoter of the beta-2 subunit of the neuronal nicotinic acetylcholine receptor to activate transcription (Choi *et al.* 2008; Du *et al.* 1998). Finally, morphine can stimulate hnRNP K translation in multiple brain regions independent from transcription (Lee *et al.* 2014).

To summarize, PCBPs and hnRNP K are associated with neurodevelopment, catecholaminergic, monoaminergic, opioidergic and cholinergic signaling and, thus, are prime suspects in regulating neurotransmitter signaling underlying the addictions. Importantly, post-translational modifications can also significantly impact cell function of PCBPs. A notable example is ERK-induced phosphorylation of hnRNP K, which translocates hnRNP K to the cytoplasm where it can then bind to the 3′ UTR of mRNAs to regulate protein translation (Habelhah et al. 2001). Therefore, therapeutic modulation of hnRNP K signaling could be a future treatment avenue in the addictions.

## PTBPs (including PTBP-1; a.k.a. hnRNP I)

Polypyrimidine tract-binding proteins (PTBPs) bind to both intronic and exonic polypyrimidine tract sequences to repress exon inclusion. They contain four RRMs, an NLS and an NES in the N-terminus that permit alternative splicing, shuttling, polyadenylation, transport, localization, stabilization and translation (Keppetipola et al. 2012; Romanelli et al. 2013). RRM-1 and RRM-2 are separated by flexible linkers that permit independent conformations whereas RRM-3 and -4 form a globular structure and binds to nearby, intervening pyrimidine tracts to induce RNA looping (Romanelli et al. 2013). Alternatively spliced isoforms of PTBP1 can contain longer intervening domains or isoforms that lack RRM-1 and -2, thus diversifying PTBP targets and function within the context of an RNP complex. Splicing repression by PTBP can depend on its proximity to the splice site, its antagonism by other RBP splicing co-factors such as CELF proteins (Gromak et al. 2003; Spellman et al. 2005) and neuro-oncological ventral antigen1 (Nova1) (Polydorides et al. 2000), and its interaction with co-repressors such as the Raver proteins (Henneberg et al. 2010). In addition to splicing, PTBP1 can bind directly to 3′ UTRs to regulate cleavage in polyadenylation, 3′ UTR exon inclusion and mRNA stability (Sawicka et al. 2008). Finally, PTBPs interact with PCBPs and act at the internal ribosomal entry site to initiate translation (Bushell et al. 2006).

During neurodevelopment, reciprocal changes in PTBP1 and 2 expression coordinate differential splicing of PSD-95 to control the timing of neuronal differentiation (Zheng et al. 2012). PTBP1 is expressed in neural progenitors and decreases during differentiation and is restricted to glia during adulthood. In contrast, expression of the gene paralog PTBP2 increases during neuronal differentiation, decreases during cortical maturation and shows moderate neuronal expression during adulthood (Keppetipola et al. 2012). Notably, PTBP1 inhibits the expression of PSD-95 in neural progenitors whereby it represses the inclusion of a coding exon which results in nonsense-mediated decay and delays excitatory synapse stabilization and maturation (Keppetipola et al. 2012; Zheng et al. 2012). A similar mechanism is used by PTBPs to inhibit their own expression (Boutz et al. 2007). PTBP2 is essential for postnatal survival and genome-wide RNA target analysis of the developing mouse brain revealed that PTBP2 inhibits a splicing program involved in neuronal cell cycle,

proliferation, actin cytoskeleton and neuronal differentiation (Licatalosi et al. 2012).

With regard to dopamine receptors and the addictions, the short and long splice forms of the D2 dopamine receptor (D2L and D2S) are highly conserved and have different signaling properties and physiological function (Picetti et al. 1997) that have been associated with the addictions (Levran et al. 2015; Smith et al. 2002). Both PTBP1 and Nova1 promote exon 6 inclusion whereas hnRNP M inhibits exon 6 inclusion, thus bidirectionally regulating D2L vs. D2S expression (Park et al. 2011; Sasabe et al. 2011). Overexpression of PTBP1 in vitro was associated with a decrease in transcription of ΔfosB, a stable splice variant of the transcription factor fosB that accumulates in the nucleus accumbens following chronic administration of drugs of abuse and is associated with sustained drug-induced synaptic plasticity (Alibhai et al. 2007; Nestler et al. 2001). Thus, perhaps post-translationally modifying PTBP1, e.g. via phosphorylation and cytoplasmic translocation (Xie et al. 2003), could modulate ΔfosB-mediated neuroplasticity associated with the addictions.

## ELAVL

The neuronal-specific mammalian embryonic lethal, abnormal vision-like (ELAVL)2, 3 and 4 RBPs are an RBP family based on homology to ELAV protein in *Drosophila* (Robinow et al. 1988) and regulate the transport, stabilization, localization and translation of mRNAs. They contain three RRMs that mediate binding to intronic targets for splicing as well as binding to highly conserved AU-rich element (ARE) sequences of 3′ UTR targets to regulate stability (Colombrita et al. 2013), including Nova1 (Ratti et al. 2008). ELAVL4 can also enhance cap-dependent translation via structural unwinding of 5′ UTRs (Fukao et al. 2009). ELAVL RBPs contribute to all stages of neuronal differentiation, maintenance, synaptogenesis and activity-dependent synaptic plasticity (Perrone-Bizzozero & Bolognani 2002). The localization of ELAVL RBPs in the neocortex and hippocampus (Okano & Darnell 1997) suggests potential involvement in neurodevelopmental and neuroanatomical risk for the addictions (Andersen & Teicher 2009). RNA-binding protein target analysis of ELAVL of mouse forebrain tissue identified a spliceome enriched for axonal and synaptic cytoskeleton dynamics and 3′ UTR-regulated genes involved in amino acid synthesis. Of note, ELAVL regulates the splicing and half-life of glutaminase, indicating an essential role in excitatory neurotransmission (Ince-Dunn et al. 2012).

Acute cocaine treatment caused a decrease in whole-brain FMRP expression and an increase in ELAVL expression that was associated with an increase in expression of genes enriched for dendritic synaptic plasticity (Tiruchinapalli et al. 2008). Combining repeated cocaine administration with swim stress increased ELAVL4 phosphorylation and translation in the hippocampus as well as expression of its canonical cytoskeletal target, growth-associated protein (GAP)-43 (Pascale et al. 2011), which could contribute to structural plasticity and drug-associative learning (Bolognani et al. 2007). Importantly, ELAVL4 selectively binds to

the unique ARE sequence of the long 3′ UTR but not the short 3′ UTR of BDNF mRNA to increase BDNF stability and activity-dependent translation (Allen *et al.* 2013). The increase in BDNF translation is mediated by PKC-induced phosphorylation of ELAVL4, which disinhibits 3′ UTR-mediated translational repression of the long 3′ UTR BDNF mRNA in hippocampal neuronal dendrites (Vanevski & Xu 2015). Selective regulation of the long 3′ UTR of BDNF is important because it is responsible for activity-dependent neuronal translation of BDNF (Lau *et al.* 2010) and synaptic maturation in the dendrites (An *et al.* 2008). Psychostimulant administration increases the expression of BDNF (Russo *et al.* 2009) and in turn, BDNF can regulate neuronal expression of FMRP and synaptic protein translation (Castren & Castren 2014). Thus, an ELAVL-mediated increase in activity-dependent translation of BDNF and other mRNA targets may work in parallel with FMRP to induce neurobehavioral plasticity in response to drugs of abuse (Smith *et al.* 2014). Interestingly, an increase in BDNF expression may serve as a biomarker for severity of psychostimulant addiction and vulnerability to relapse in recently abstinent individuals (Sinha 2011).

## ZBP1

Zipcode-binding protein-1 (ZBP1) is a cytoplasmic protein that shuttles between the nucleus and cytoplasm via its NES and NLS sequence. ZBP2 is a second, homologous RBP that is localized to the nucleus and cooperates with ZBP1 to shuttle beta-actin mRNA into the cytoplasm (Gu *et al.* 2002; Pan *et al.* 2007). ZBPs share significant homology with PCBPs and contain two RRMs and four KH-type RNA-binding motifs. KH3 and KH4 domains of ZBP1 form a pseudodimer that recognizes a 54-nucleotide zipcode sequence on the 3′ UTR of beta-actin mRNA for transport and translation in dendrites (Doyle & Kiebler 2012; Farina *et al.* 2003; Gu *et al.* 2002; Huttelmaier *et al.* 2005; Ross *et al.* 1997).

ZBP1 represses beta-actin translation in the cytoplasm that is relieved upon Src phosphorylation at Tyr396 (Huttelmaier *et al.* 2005). Both BDNF and netrin-1 stimulate phosphorylation of ZBP1 at Tyr396 and increased protein synthesis of beta-actin in a model of axon guidance in cortical neurons (Sasaki *et al.* 2010; Welshhans & Bassell 2011). Neurodevelopmental studies demonstrate ZBP1 transport and localization of beta-actin in synaptogenesis of dendritic filopodia (Eom *et al.* 2003) and neurotrophin-induced growth cone motility (Zhang *et al.* 2001). Furthermore, ZBP1 is necessary for NMDA receptor-dependent targeting of beta-actin mRNA to the hippocampal dendrites (Tiruchinapalli *et al.* 2003) as well as dendritic arborization induced by Src-induced ZBP1 phosphorylation and relief of translational repression (Perycz *et al.* 2011). In addition to dendritic plasticity, axonal regeneration in severed sensory neurons involves ZBP1-mediated transport of both beta-actin and GAP-43 mRNAs to localize protein synthesis and increase axonal growth and branching, respectively (Donnelly *et al.* 2011, 2013).

Similar to ELAVL-associated increased expression of GAP-43 following *in vivo* administration of cocaine and

stress (Pascale *et al.* 2011), *in vivo* axonal injury induced an increased in the expression of GAP-43 that interacts with ELAVL4 as well as ZBP1 in a complex to induce axonal outgrowth and branching (Yoo *et al.* 2013). It was recently shown that although both ZBP1 and ELAVL4 interact with beta-actin, ELAVL4 binds specifically to the ARE sequence in the 3′ UTR whereas ZBP1 requires a specific secondary structure (Kim *et al.* 2015) that could permit its ability to form a EVAL/ZBP complex in neuroplasticity underlying axonal regeneration and possibly cocaine neuroplasticity. In further support of a link between ZBP1 and cocaine, transgenic, ectopic expression of ZBP1 in the striatum during adulthood blocked cocaine-induced conditioned place preference that was rescued by eliminating ZBP1 expression. Direct, experimental target analysis identified nearly 200 transcripts involved in synaptic plasticity that could be responsible for the effect of ZBP1 on cocaine reward, including the scaffolding gene *Homer1* that negatively regulates cocaine reward (Szumlinski *et al.* 2004) as well as cadherins, transcription factors, kinases, ion channels and Ras members (Lapidus *et al.* 2012). Interestingly, we previously identified both a behavioral QTL and a *cis*-acting eQTL from striatal tissue on chromosome 11 for *Igf2bp1* (insulin growth factor 2 mRNA-binding protein 1; the gene coding for ZBP1 protein) that was causally associated with reduced methamphetamine-induced locomotor activity and increased *Igf2bp1* expression. In light of the recent ZBP1 findings discussed above, *Igf2bp1* could represent a quantitative trait gene underlying methamphetamine stimulant sensitivity (Bryant *et al.* 2012).

An intriguing possibility is that native ZBP1 expression could be reawakened in the mature brain following chronic exposure to drugs of abuse and regulate a neurodevelopmental program that underlies certain addictions such as cocaine (Dong & Nestler 2014). Furthermore, based on the combined evidence described above, ZBP1 could promote BDNF-mediated structural recovery of damaged catecholaminergic and monoaminergic axons following administration of neurotoxic drugs such as methamphetamine and MDMA (Adori *et al.* 2010; Ares-Santos *et al.* 2014).

## RBFOX1 (A2BP1)

RBFOX (RNA-binding protein, fox-1 homolog) proteins are neuronal splicing factors that promote both exon inclusion and skipping that depends on the position of the canonical UGCAUG binding motif near the exon (Underwood *et al.* 2005; Zhang *et al.* 2008). RBFOX proteins contain a highly conserved, identical RRM that is responsible for binding RNAs and less conserved regions in the N-terminus and NLS-containing C-terminus that also dictate splicing of RBFOX proteins themselves and other proteins that can govern subcellular localization and increase the functional diversity of these RBPs (Kuroyanagi 2009).

Genome-wide target analysis of RBFOX2 in human embryonic stem cells identified several RBP splicing factors as targets, including hnRNP A2/B1, H1, H2 and PTBP (Yeo *et al.* 2009), which emphasizes the high degree of network connectivity in genomic coordination of RBP splicing (Huelga

*et al.* 2012). Enrichment analysis of the predicted RBFOX spliceome revealed sets of genes involved in neuromuscular, cytoskeleton, ion channel and phosphorylation functions (Zhang *et al.* 2008). Experimental identification of direct RBFOX targets in the mouse brain identified intronic splicing targets and 3′ UTR targets that could regulate alternative polyadenylation and mRNA stability. RBFOX targets were enriched for cytoskeleton anchoring, scaffolding and signaling, and neuronal projections. Increased expression of RBFOX1 and RBFOX3 and decreased expression of RBFOX2 were associated with a change in the RBFOX spliceome programs from E17 to adulthood (Weyn-Vanhentenryck *et al.* 2014).

RBFOX1 is a neurodevelopmental splicing RBP whose dysfunction is associated with autism, intellectual disability, ADHD, bipolar disorder and schizophrenia (Bill *et al.* 2013; Fogel *et al.* 2012). CNS-specific knockout of *Rbfox1* in mice resulted in enhanced hippocampal neuronal excitability and susceptibility to seizures, demonstrating a role for RBFOX1 in neuronal excitation and synaptic transmission (Gehman *et al.* 2011). RBFOX1 is expressed throughout development in the mouse and human basal forebrain, neocortex and hippocampus (Fogel *et al.* 2012; Hammock & Levitt 2011). Spliceome and transcriptome analysis of differentiated primary human neural progenitor cells following RBFOX1 knockdown identified parallel networks of transcription factors, splicing factors and synaptic proteins involved in neurogenesis, neurodevelopment, maintenance, cytoskeletal organization and cell adhesion, projection, proliferation and synapse function. Notably, differential splicing was observed for several genes coding for RBPs, including *HNRNPD*, *HNRNPA1*, *ELAVL2* and *HNRNPH1* (Fogel *et al.* 2012), which in turn was associated with a perturbation in their predicted splicing programs based on their RNA-binding motifs. For example, 205 of the total 996 alternative splicing events that were identified following RBFOX1 knockdown contained the binding site for hnRNP H1, suggesting that RBFOX1 regulates the splicing of *HNRNPH1* (Fogel *et al.* 2012). Conversely, hnRNP H1 regulates the splicing activity of *RBFOX1/2* by interacting with the C-terminal domain (Sun *et al.* 2012). In addition to splicing *HNRNPH1*, RBFOX2 can form a complex with hnRNP H1 and F to silence splicing of other genes (Mauger *et al.* 2008). Thus, hnRNP H1 and RBFOX proteins could coordinate splicing in affecting methamphetamine stimulant behavior (Yazdani *et al.* 2015) and heroin addiction (Xu *et al.* 2014).

Recent, direct evidence implicating RBFOX in the nucleus accumbens in the addictions comes from a genome-wide transcriptomic and epigenomic study of chronic cocaine administration in mice that identified a translocation of RBFOX1 to the nucleus which was associated with an increase in splicing events that coincided with the location of histone modifications. Furthermore, site-specific Cre-mediated knockdown in the nucleus accumbens of floxed RBFOX1 mice blocked cocaine reward (Feng *et al.* 2014), which together suggests that that RBFOX1 coordinates an adaptive splicing program underlying cocaine dependence. Interestingly, RBFOX1 variants have been nominally associated with nicotine dependence, alcohol dependence and cocaine reward and regulate the splicing of cell adhesion molecule genes in dopaminergic neurons

that are associated with neurodevelopmental connectivity, plasticity and genetic variation underlying the addictions (Zhong *et al.* 2015).

## CELF4 and CELF6

CELF (CUG-BP, ELAV-like factor) is a family of highly expressed multifunctional RBPs in the brain that have both nuclear splicing and cytoplasmic functions in RNA processing. CELF and ELAV can cooperatively promote splicing in mammalian neurons and a recent study in *Caenorhabditis elegans* indicates that they co-regulate overlapping and distinct splicing networks to determine cholinergic vs. GABAergic neuronal cell type (Norris *et al.* 2014). CELF RBPs bind to pyrimidine-rich sequences and compete with PTBPs to activate splicing (Gromak *et al.* 2003; Spellman *et al.* 2005). Notably, the high sequence similarity between hnRNP A1 vs. CELF1 suggests shared functions (Tang *et al.* 2012). CELF RBPs contain highly conserved RNA recognition motifs (RRM)-1 and -2 at the N-terminus and a third RRM at the C-terminus (Dasgupta & Ladd 2012). RRM-1 and -2 are separated from RRM-3 by a non-conserved divergent linker domain that differentiates CELF1-2 from CELF 3–6 in determining RNA–protein and protein–protein interactions in forming target-specific RNP complexes (Dasgupta & Ladd 2012; Gallo & Spickett 2010). The RRMs contain RNP motifs that typically bind to introns, 3′ UTRs and 5′ UTRs of mRNAs to regulate splicing, poly(A)-specific ribonuclease recruitment and deadenylation [e.g. with c-fos (Moraes *et al.* 2006)], polyadenylation, mRNA stability and translation (Dasgupta & Ladd 2012). Both the divergent domain and C-terminus contain the signals that determine nuclear vs. cytosolic localization of CELF1 and CELF2 (Fujimura *et al.* 2008; Ladd & Cooper 2004). Importantly, CELF proteins contain multiple phosphorylation sites that regulate protein and RNA interactions to influence protein stability, localization and translation of CELF targets (Dasgupta & Ladd 2012).

CELF RBPs are linked to several neurological and neurodegenerative disorders, as well as neurodevelopmental and neuropsychiatric disorders, including social communication problems in autism (CELF4, CELF6), epilepsy (CELF4), bipolar disorder (CELF5) and schizophrenia (CELF5) (Dougherty *et al.* 2013; Ladd 2013; Welter *et al.* 2014). Recent evidence implicates both CELF4 and CELF6 in the addictions. CELF4 is a brain-specific isoform that is expressed throughout development and is highly expressed in the hippocampus, amygdala and cortex. CELF4 loss of function in mice causes seizures (Yang *et al.* 2007) and a functional deficit in excitatory synaptic transmission in cortical and hippocampal neurons (Wagnon *et al.* 2011). The complex seizure phenotype implicates a role for CELF4 in corticothalamic development (Wagnon *et al.* 2011). RNA target analysis of CELF4 in cortical and hippocampal tissue identified several 3′ UTR-targeted mRNAs involved in synaptic transmission (Wagnon *et al.* 2012). Of potential relevance to the addictions, genetic variation in *CELF4* showed a nominal association ($P = 3$–$5 \times 10^{-6}$) with the subjective amphetamine response (Hart *et al.* 2012) and has been linked to hyperphagia-related obesity (Comuzzie *et al.* 2012; Halgren *et al.* 2012).

Translational profiling of ribosome-bound mRNAs from mouse serotonergic neurons combined with analysis of human genetic variants identified *CELF6* as a candidate gene associated with autism. *Celf6* knockouts exhibit reduced brain serotonin, deficits in ultrasonic vocalizations in neonatal pups and behavioral resistance to change (Dougherty *et al.* 2013). CELF6 is expressed in both the nucleus and cytoplasm throughout development and exhibits localized expression in monoaminergic and catecholaminergic cells in the basal forebrain, ventral tegmental area, substantia nigra, raphe nuclei and locus coeruleus (Maloney *et al.* 2015). Thus, *Celf6* could influence neurodevelopment and function of the mesocorticolimbic reward circuitry. In support, *Celf6* knockouts show a disruption of conditioned cocaine reward (Dougherty 2015). *CELF6* can promote both exon inclusion and skipping (Ladd *et al.* 2004). It will be important to determine the direct nuclear and cytoplasmic targets of *CELF6*, which will provide insight into the subcellular mechanisms of behavioral and psychiatric dysfunction.

## ADAR1/2

RNA editing is yet another type of distinct and adaptive pre-mRNA processing mechanism that can increase proteome diversity to regulate neurodevelopment, plasticity and human disease, including neurological and psychiatric disorders such as schizophrenia, bipolar disorder and depression (Li & Church 2013). Adenosine deaminase acting on RNA (ADAR)-1, 2 and 3 are nuclear, enzymatic RBPs that contain double-stranded RNA-binding motifs and destabilize pre-mRNA to 'edit' adenosine (A) nucleotides to guanosine-mimicking RNA inosine (I) nucleotides. A–I editing changes the complementary nucleotide to cytosine, thus modulating RNA base pairing and potentially splice site, transport, ribosome binding, translational efficiency and amino acid sequence (Li & Church 2013; Slotkin & Nishikura 2013). Compared to extensive editing of non-coding RNA, recoding of coding exons is rare in mammals and these sites are enriched for proteins involved in neuronal function, including neuronal excitability, vesicular release and cytoskeleton architecture (Rosenthal 2015). The expansion of RNA editing from rodents to non-human primates to humans suggests an important role in brain evolution and cognition (Li & Church 2013). Although the regulation of ADAR in RNA editing is poorly understood, it is relevant to note that FMRP interacts with ADAR in *Drosophila* to modulate enzymatic activity and editing of mRNA transcripts that affect synaptic morphology (Bassell 2011; Bhogal *et al.* 2011). This observation highlights an additional function of FMRP and suggests that FMRP and ADAR could work together in neurodevelopment and neuroplasticity in the addictions.

ADAR2 has an established role in editing of the GluA2 subunit of the AMPA receptor at Q/R site 607 which reduces calcium permeability (Geiger *et al.* 1995) and may protect against neuronal excitotoxicity *in vivo* (Higuchi *et al.* 2000). With regard to the addictions, cocaine abstinence and cocaine-primed reinstatement of self-administration in rats have been associated with decreased ADAR2 expression and decreased GluA2 editing of the Q/R site in the nucleus accumbens shell. Overexpression of ADAR2 prevented relapse and the concomitant increase in surface receptor expression of AMPAR (Schmidt *et al.* 2014). Thus, unedited AMPAR receptors are associated with a model of drug relapse that could be mitigated by restoration of surface-edited AMPA receptors.

In addition to AMPA receptor editing, ADAR proteins also edit the 5-HT2C receptor [a promising drug target for treating addictive disorders (Higgins & Fletcher 2015)] at five different sites within the second intracellular loop, yielding up to 24 brain region-specific isoforms that could alter pre-mRNA splicing, ligand affinity, ligand-induced g-protein signaling, ligand-induced blockade of constitutive activity and brain region-specific functions, including modulation of dopamine release (Burns *et al.* 1997; Werry *et al.* 2008). Interestingly, rats categorized as high vs. low novelty seeking (a trait that correlates with future drug use) show differences in 5-HT2C receptor editing in the mesocorticolimbic circuitry, in particular the nucleus accumbens shell that could affect dopamine transmission (Dracheva *et al.* 2009). An increase in alcohol drinking in different mouse strains was associated with an increase in anxiety as well as an increase in ADAR1/2 expression and 5-HT2C editing in the nucleus accumbens and dorsal raphe nucleus (Watanabe *et al.* 2014). Finally, chronic nicotine decreased editing of the 5-HT2C in the hippocampus that was associated with depressive-like behavior during nicotine withdrawal (Zaniewska *et al.* 2010, 2015). Thus, differential 5-HT2C receptor editing could potentially predispose individuals to addiction risk as well as mediate the negative emotional states that support addictive behaviors.

An increase in 5-HT2C receptor editing is associated with hyperphagia and obesity in patients with Prader–Willi syndrome and in mice expressing the fully edited 5-HT2C receptor (Kawahara *et al.* 2008). Furthermore, mice that differentially express the wild-type or catalytically inactive version of ADAR2 show hyperphagia and obesity (Singh *et al.* 2007) and increased preference for high fat food over running (Akubuiro *et al.* 2013). These physiological and behavioral changes indicate a food 'addiction' propensity that is supported by increased mRNA expression of ADAR2, D1 and D2 dopamine receptors, MOR, 5-HT2C long and short splice variants in the hypothalamus as well as increased mRNA expression of D1 dopamine receptors in the striatum. Positron emission tomography imaging in mice using a tail vein injection of [$^{18}$F]-fluorodeoxyglucose indicated an increase in glucose metabolism in the mesolimbic reward circuitry, hypothalamus and hippocampus. The combined observations implicate hyperactive food-directed reward processing in ADAR2 transgenics (Akubuiro *et al.* 2013; Singh *et al.* 2011); however, direct evidence linking RNA editing to food or drug addictive behaviors is still lacking.

To summarize, changes in AMPA receptor and 5-HT receptor editing are associated with exposure to abused substances and could contribute to susceptibility and synaptic plasticity underlying the addictions. Future studies will likely involve the use of advanced genome editing approaches to directly test the causal, spatiotemporal role of recoded proteins as well as non-coding RNAs in the brain in the establishment and maintenance of addictive behaviors.

**Figure 2: RNA-binding proteins implicated in the addictions.** Many RBPs have the capability to shuttle between the nucleus and cytoplasm to regulate all levels of RNA post-transcriptional processing. Here, we illustrate the location of action of the main examples that are discussed and some of their well-characterized targets. For the RBPs that are illustrated, we have also indicated whether they contribute to axon development by listing them in the axon terminal (bottom). The yellow rectangles denote dendrites. The blue spikes indicate an association with structural changes in dendritic morphology.

## Summary

This review highlights the diversity of RBP functions in regulating transcription, RNA metabolism, neurodevelopment and neuroplasticity relevant to the addictions (Fig. 2). Although beyond the scope of this review, RBPs also interact with non-coding RNAs and there are several new and emerging RNA modifications that could be of relevance to the addictions (Satterlee *et al.* 2014). Identifying the key cell type-specific splice forms and unique functions of RBP splice variants and their alternatively spliced targets will be critical to yielding novel, biologically relevant discoveries in the addictions. Do a specific set of RBPs become recruited during environmental stress exposure or drug exposure that influence addiction risk? What are the transcriptomes, spliceomes and translatomes (King & Gerber 2014) that these RBPs govern in response to risk exposure, drug exposure and the interactive exposure to both? How do these programs change across neurodevelopment, across repeated drug exposure as addiction progress and across recovery during abstinence? In addition to splicing, post-translational modifications of RBPs, including phosphorylation, ubiquitination, sumoylation and methylation, can further regulate the transport, stabilization, degradation and binding of RBPs to their RNA targets and to other proteins (Chaudhury *et al.* 2010), thus adding additional layers of regulation in RBP function. This complexity may one day be harnessed to perturb RBP signaling in preventing and treating the addictions as has recently been demonstrated in other disease models (Kim *et al.* 2014; Wang *et al.* 2009).

We limited our discussion to RBPs where multiple lines of evidence implicate a potential importance in the addictions. However, additional RBPs are certainly going to be uncovered in the addictive process from neurodevelopment to drug-induced neuroplasticity. For instance, cytoplasmic

polyadenylation element-binding proteins (CPEBs) play an important role in synaptic plasticity (Ivshina *et al.* 2014). Second, the SR protein Tra2$\beta$ can be spliced by the dopamine signaling molecule DARPP-32 (Benderska *et al.* 2010) and can promote splicing of RGS proteins (regulators of g-protein signaling) in response to morphine (Li *et al.* 2013; Traynor 2010). Third, KH-type Nova proteins also regulate splicing of the D2 dopamine receptor and neocortical synaptic proteins involved in neurotransmitter release and signaling, receptor localization, synaptogenesis, axonogenesis, actin organization, cell adhesion and extracellular matrix organization (Park *et al.* 2011; Ule *et al.* 2005).

The topic of RBPs and the addictions is clearly a wide open and promising field of research; understanding how these remarkable proteins coordinate splicing and translation during neurodevelopment and neuroplasticity promises to yield dividends in understanding and treating neuropsychiatric diseases.

# References

Adori, C., Ando, R.D., Ferrington, L., Szekeres, M., Vas, S., Kelly, P.A., Hunyady, L. & Bagdy, G. (2010) Elevated BDNF protein level in cortex but not in hippocampus of MDMA-treated Dark Agouti rats: a potential link to the long-term recovery of serotonergic axons. *Neurosci Lett* **478**, 56–60.

Akubuiro, A., Bridget Zimmerman, M., Boles Ponto, L.L., Walsh, S.A., Sunderland, J., McCormick, L. & Singh, M. (2013) Hyperactive hypothalamus, motivated and non-distractible chronic overeating in ADAR2 transgenic mice. *Genes Brain Behav* **12**, 311–322.

Alibhai, I.N., Green, T.A., Potashkin, J.A. & Nestler, E.J. (2007) Regulation of fosB and DeltafosB mRNA expression: in vivo and in vitro studies. *Brain Res* **1143**, 22–33.

Allen, M., Bird, C., Feng, W., Liu, G., Li, W., Perrone-Bizzozero, N.I. & Feng, Y. (2013) HuD promotes BDNF expression in brain neurons via selective stabilization of the BDNF long 3'UTR mRNA. *PLoS One* **8**, e55718.

An, J.J., Gharami, K., Liao, G.Y., Woo, N.H., Lau, A.G., Vanevski, F., Torre, E.R., Jones, K.R., Feng, Y., Lu, B. & Xu, B. (2008) Distinct role of long 3' UTR BDNF mRNA in spine morphology and synaptic plasticity in hippocampal neurons. *Cell* **134**, 175–187.

Andersen, S.L. & Teicher, M.H. (2009) Desperately driven and no brakes: developmental stress exposure and subsequent risk for substance abuse. *Neurosci Biobehav Rev* **33**, 516–524.

Ares-Santos, S., Granado, N., Espadas, I., Martinez-Murillo, R. & Moratalla, R. (2014) Methamphetamine causes degeneration of dopamine cell bodies and terminals of the nigrostriatal pathway evidenced by silver staining. *Neuropsychopharmacology* **39**, 1066–1080.

Banerjee, K., Wang, M., Cai, E., Fujiwara, N., Baker, H. & Cave, J.W. (2014) Regulation of tyrosine hydroxylase transcription by hnRNP K and DNA secondary structure. *Nat Commun* **5**, 5769.

Bassell, G.J. (2011) Fragile balance: RNA editing tunes the synapse. *Nat Neurosci* **14**, 1492–1494.

Bear, M.F., Huber, K.M. & Warren, S.T. (2004) The mGluR theory of fragile X mental retardation. *Trends Neurosci* **27**, 370–377.

Benderska, N., Becker, K., Girault, J.A., Becker, C.M., Andreadis, A. & Stamm, S. (2010) DARPP-32 binds to tra2-beta1 and influences alternative splicing. *Biochim Biophys Acta* **1799**, 448–453.

Bhogal, B., Jepson, J.E., Savva, Y.A., Pepper, A.S., Reenan, R.A. & Jongens, T.A. (2011) Modulation of dADAR-dependent RNA editing by the Drosophila fragile X mental retardation protein. *Nat Neurosci* **14**, 1517–1524.

Bill, B.R., Lowe, J.K., Dybuncio, C.T. & Fogel, B.L. (2013) Orchestration of neurodevelopmental programs by RBFOX1: implications for autism spectrum disorder. *Int Rev Neurobiol* **113**, 251–267.

Blanchette, A.R., Fuentes Medel, Y.F. & Gardner, P.D. (2006) Cell-type-specific and developmental regulation of heterogeneous nuclear ribonucleoprotein K mRNA in the rat nervous system. *Gene Expr Patterns* **6**, 596–606.

Bolognani, F., Qiu, S., Tanner, D.C., Paik, J., Perrone-Bizzozero, N.I. & Weeber, E.J. (2007) Associative and spatial learning and memory deficits in transgenic mice overexpressing the RNA-binding protein HuD. *Neurobiol Learn Mem* **87**, 635–643.

Boschi, N.M., Takeuchi, K., Sterling, C. & Tank, A.W. (2015) Differential expression of polycytosine-binding protein isoforms in adrenal gland, locus coeruleus and midbrain. *Neuroscience* **286**, 1–12.

Boutz, P.L., Stoilov, P., Li, Q., Lin, C.H., Chawla, G., Ostrow, K., Shiue, L., Ares, M. Jr. & Black, D.L. (2007) A post-transcriptional regulatory switch in polypyrimidine tract-binding proteins reprograms alternative splicing in developing neurons. *Genes Dev* **21**, 1636–1652.

Bryant, C.D., Kole, L.A., Guido, M.A., Sokoloff, G. & Palmer, A.A. (2012) Congenic dissection of a major QTL for methamphetamine sensitivity implicates epistasis. *Genes Brain Behav* **11**, 623–632.

Burns, C.M., Chu, H., Rueter, S.M., Hutchinson, L.K., Canton, H., Sanders-Bush, E. & Emeson, R.B. (1997) Regulation of serotonin-2C receptor G-protein coupling by RNA editing. *Nature* **387**, 303–308.

Bushell, M., Stoneley, M., Kong, Y.W., Hamilton, T.L., Spriggs, K.A., Dobbyn, H.C., Qin, X., Sarnow, P. & Willis, A.E. (2006) Polypyrimidine tract binding protein regulates IRES-mediated gene expression during apoptosis. *Mol Cell* **23**, 401–412.

Campos-Melo, D., Galleguillos, D., Sanchez, N., Gysling, K. & Andres, M.E. (2013) Nur transcription factors in stress and addiction. *Front Mol Neurosci* **6**, 44.

Casey, B.J., Glatt, C.E., Tottenham, N., Soliman, F., Bath, K., Amso, D., Altemus, M., Pattwell, S., Jones, R., Levita, L., McEwen, B., Magarinos, A.M., Gunnar, M., Thomas, K.M., Mezey, J., Clark, A.G., Hempstead, B.L. & Lee, F.S. (2009) Brain-derived neurotrophic factor as a model system for examining gene by environment interactions across development. *Neuroscience* **164**, 108–120.

Castren, M.L. & Castren, E. (2014) BDNF in fragile X syndrome. *Neuropharmacology* **76** (Pt C), 729–736.

Castren, M., Lampinen, K.E., Miettinen, R., Koponen, E., Sipola, I., Bakker, C.E., Oostra, B.A. & Castren, E. (2002) BDNF regulates the expression of fragile X mental retardation protein mRNA in the hippocampus. *Neurobiol Dis* **11**, 221–229.

Ceman, S., O'Donnell, W.T., Reed, M., Patton, S., Pohl, J. & Warren, S.T. (2003) Phosphorylation influences the translation state of FMRP-associated polyribosomes. *Hum Mol Genet* **12**, 3295–3305.

Chaudhury, A., Chander, P. & Howe, P.H. (2010) Heterogeneous nuclear ribonucleoproteins (hnRNPs) in cellular processes: focus on hnRNP E1's multifunctional regulatory roles. *RNA* **16**, 1449–1462.

Choi, H.S., Kim, C.S., Hwang, C.K., Song, K.Y., Law, P.Y., Wei, L.N. & Loh, H.H. (2007) Novel function of the poly(C)-binding protein alpha CP3 as a transcriptional repressor of the mu opioid receptor gene. *FASEB J* **21**, 3963–3973.

Choi, H.S., Song, K.Y., Hwang, C.K., Kim, C.S., Law, P.Y., Wei, L.N. & Loh, H.H. (2008) A proteomics approach for identification of single strand DNA-binding proteins involved in transcriptional regulation of mouse mu opioid receptor gene. *Mol Cell Proteomics* **7**, 1517–1529.

Choi, H.S., Hwang, C.K., Song, K.Y., Law, P.Y., Wei, L.N. & Loh, H.H. (2009) Poly(C)-binding proteins as transcriptional regulators of gene expression. *Biochem Biophys Res Commun* **380**, 431–436.

Chou, M.Y., Rooke, N., Turck, C.W. & Black, D.L. (1999) hnRNP H is a component of a splicing enhancer complex that activates a c-src alternative exon in neuronal cells. *Mol Cell Biol* **19**, 69–77.

Cleva, R.M., Gass, J.T., Widholm, J.J. & Olive, M.F. (2010) Glutamatergic targets for enhancing extinction learning in drug addiction. *Curr Neuropharmacol* **8**, 394–408.

Colombrita, C., Silani, V. & Ratti, A. (2013) ELAV proteins along evolution: back to the nucleus? *Mol Cell Neurosci* **56**, 447–455.

Comuzzie, A.G., Cole, S.A., Laston, S.L., Voruganti, V.S., Haack, K., Gibbs, R.A. & Butte, N.F. (2012) Novel genetic loci identified for the

pathophysiology of childhood obesity in the Hispanic population. *PLoS One* **7**, e51954.

Contet, C., Kieffer, B.L. & Befort, K. (2004) Mu opioid receptor: a gateway to drug addiction. *Curr Opin Neurobiol* **14**, 370–378.

Czyzyk-Krzeska, M.F. & Beresh, J.E. (1996) Characterization of the hypoxia-inducible protein binding site within the pyrimidine-rich tract in the 3′-untranslated region of the tyrosine hydroxylase mRNA. *J Biol Chem* **271**, 3293–3299.

Darnell, J.C. & Klann, E. (2013) The translation of translational control by FMRP: therapeutic targets for FXS. *Nat Neurosci* **16**, 1530–1536.

Darnell, J.C., Van Driesche, S.J., Zhang, C., Hung, K.Y., Mele, A., Fraser, C.E., Stone, E.F., Chen, C., Fak, J.J., Chi, S.W., Licatalosi, D.D., Richter, J.D. & Darnell, R.B. (2011) FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. *Cell* **146**, 247–261.

Dasgupta, T. & Ladd, A.N. (2012) The importance of CELF control: molecular and biological roles of the CUG-BP, Elav-like family of RNA-binding proteins. *Wiley Interdiscip Rev RNA* **3**, 104–121.

De Rubeis, S., Pasciuto, E., Li, K.W., Fernandez, E., Di Marino, D., Buzzi, A., Ostroff, L.E., Klann, E., Zwartkruis, F.J., Komiyama, N.H., Grant, S.G., Poujol, C., Choquet, D., Achsel, T., Posthuma, D., Smit, A.B. & Bagni, C. (2013) CYFIP1 coordinates mRNA translation and cytoskeleton remodeling to ensure proper dendritic spine formation. *Neuron* **79**, 1169–1182.

Dichter, G.S., Damiano, C.A. & Allen, J.A. (2012) Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: animal models and clinical findings. *J Neurodev Disord* **4**, 19.

Dong, Y. & Nestler, E.J. (2014) The neural rejuvenation hypothesis of cocaine addiction. *Trends Pharmacol Sci* **35**, 374–383.

Donnelly, C.J., Willis, D.E., Xu, M., Tep, C., Jiang, C., Yoo, S., Schanen, N.C., Kirn-Safran, C.B., van Minnen, J., English, A., Yoon, S.O., Bassell, G.J. & Twiss, J.L. (2011) Limited availability of ZBP1 restricts axonal mRNA localization and nerve regeneration capacity. *EMBO J* **30**, 4665–4677.

Donnelly, C.J., Park, M., Spillane, M., Yoo, S., Pacheco, A., Gomes, C., Vuppalanchi, D., McDonald, M., Kim, H.H., Merianda, T.T., Gallo, G. & Twiss, J.L. (2013) Axonally synthesized beta-actin and GAP-43 proteins support distinct modes of axonal growth. *J Neurosci* **33**, 3311–3322.

Dougherty, J.D. (2015) Functional analyses of Celf6 – an RNA binding protein regulating early communicative behavior. Genomic and neurobiological studies of RNA binding proteins in complex traits relevant to psychiatric disorders. In *Winter Conference on Brain Research*. Big Sky, MT USA.

Dougherty, J.D., Maloney, S.E., Wozniak, D.F., Rieger, M.A., Sonnenblick, L., Coppola, G., Mahieu, N.G., Zhang, J., Cai, J., Patti, G.J., Abrahams, B.S., Geschwind, D.H. & Heintz, N. (2013) The disruption of Celf6, a gene identified by translational profiling of serotonergic neurons, results in autism-related behaviors. *J Neurosci* **33**, 2732–2753.

Doxakis, E. (2014) RNA binding proteins: a common denominator of neuronal function and dysfunction. *Neurosci Bull* **30**, 610–626.

Doyle, M. & Kiebler, M.A. (2012) A zipcode unzipped. *Genes Dev* **26**, 110–113.

Dracheva, S., Lyddon, R., Barley, K., Marcus, S.M., Hurd, Y.L. & Byne, W.M. (2009) Editing of serotonin 2C receptor mRNA in the prefrontal cortex characterizes high-novelty locomotor response behavioral trait. *Neuropsychopharmacology* **34**, 2237–2251.

Dreyfuss, G., Matunis, M.J., Pinol-Roma, S. & Burd, C.G. (1993) hnRNP proteins and the biogenesis of mRNA. *Annu Rev Biochem* **62**, 289–321.

Dreyfuss, G., Kim, V.N. & Kataoka, N. (2002) Messenger-RNA-binding proteins and the messages they carry. *Nat Rev Mol Cell Biol* **3**, 195–205.

Du, Q., Melnikova, I.N. & Gardner, P.D. (1998) Differential effects of heterogeneous nuclear ribonucleoprotein K on Sp1- and Sp3-mediated transcriptional activation of a neuronal nicotinic acetylcholine receptor promoter. *J Biol Chem* **273**, 19877–19883.

Eom, T., Antar, L.N., Singer, R.H. & Bassell, G.J. (2003) Localization of a beta-actin messenger ribonucleoprotein complex with zipcode-binding protein modulates the density of dendritic filopodia and filopodial synapses. *J Neurosci* **23**, 10433–10444.

Farina, K.L., Huttelmaier, S., Musunuru, K., Darnell, R. & Singer, R.H. (2003) Two ZBP1 KH domains facilitate beta-actin mRNA localization, granule formation, and cytoskeletal attachment. *J Cell Biol* **160**, 77–87.

Feng, J., Wilkinson, M., Liu, X., Purushothaman, I., Ferguson, D., Vialou, V., Maze, I., Shao, N., Kennedy, P., Koo, J., Dias, C., Laitman, B., Stockman, V., LaPlant, Q., Cahill, M.E., Nestler, E.J. & Shen, L. (2014) Chronic cocaine-regulated epigenomic changes in mouse nucleus accumbens. *Genome Biol* **15**, R65.

Fernandez, E., Rajan, N. & Bagni, C. (2013) The FMRP regulon: from targets to disease convergence. *Front Neurosci* **7**, 191.

Fisette, J.F., Toutant, J., Dugre-Brisson, S., Desgroseillers, L. & Chabot, B. (2010) hnRNP A1 and hnRNP H can collaborate to modulate 5′ splice site selection. *RNA* **16**, 228–238.

Fish, E.W., Krouse, M.C., Stringfield, S.J., Diberto, J.F., Robinson, J.E. & Malanga, C.J. (2013) Changes in sensitivity of reward and motor behavior to dopaminergic, glutamatergic, and cholinergic drugs in a mouse model of fragile X syndrome. *PLoS One* **8**, e77896.

Fogel, B.L., Wexler, E., Wahnich, A., Friedrich, T., Vijayendran, C., Gao, F., Parikshak, N., Konopka, G. & Geschwind, D.H. (2012) RBFOX1 regulates both splicing and transcriptional networks in human neuronal development. *Hum Mol Genet* **21**, 4171–4186.

Folci, A., Mapelli, L., Sassone, J., Prestori, F., D'Angelo, E., Bassani, S. & Passafaro, M. (2014) Loss of hnRNP K impairs synaptic plasticity in hippocampal neurons. *J Neurosci* **34**, 9088–9095.

Fujimura, K., Kano, F. & Murata, M. (2008) Dual localization of the RNA binding protein CUGBP-1 to stress granule and perinucleolar compartment. *Exp Cell Res* **314**, 543–553.

Fukao, A., Sasano, Y., Imataka, H., Inoue, K., Sakamoto, H., Sonenberg, N., Thoma, C. & Fujiwara, T. (2009) The ELAV protein HuD stimulates cap-dependent translation in a Poly(A)- and eIF4A-dependent manner. *Mol Cell* **36**, 1007–1017.

Fulks, J.L., O'Bryhim, B.E., Wenzel, S.K., Fowler, S.C., Vorontsova, E., Pinkston, J.W., Ortiz, A.N. & Johnson, M.A. (2010) Dopamine release and uptake impairments and behavioral alterations observed in mice that model fragile X mental retardation syndrome. *ACS Chem Neurosci* **1**, 679–690.

Gallo, J.M. & Spickett, C. (2010) The role of CELF proteins in neurological disorders. *RNA Biol* **7**, 474–479.

Gehman, L.T., Stoilov, P., Maguire, J., Damianov, A., Lin, C.H., Shiue, L., Ares, M. Jr., Mody, I. & Black, D.L. (2011) The splicing regulator Rbfox1 (A2BP1) controls neuronal excitation in the mammalian brain. *Nat Genet* **43**, 706–711.

Geiger, J.R., Melcher, T., Koh, D.S., Sakmann, B., Seeburg, P.H., Jonas, P. & Monyer, H. (1995) Relative abundance of subunit mRNAs determines gating and Ca$^{2+}$ permeability of AMPA receptors in principal neurons and interneurons in rat CNS. *Neuron* **15**, 193–204.

Gerstberger, S., Hafner, M. & Tuschl, T. (2014) A census of human RNA-binding proteins. *Nat Rev Genet* **15**, 829–845.

Glatt, S.J., Cohen, O.S., Faraone, S.V. & Tsuang, M.T. (2011) Dysfunctional gene splicing as a potential contributor to neuropsychiatric disorders. *Am J Med Genet B Neuropsychiatr Genet* **156B**, 382–392.

Glisovic, T., Bachorik, J.L., Yong, J. & Dreyfuss, G. (2008) RNA-binding proteins and post-transcriptional gene regulation. *FEBS Lett* **582**, 1977–1986.

Gromak, N., Matlin, A.J., Cooper, T.A. & Smith, C.W. (2003) Antagonistic regulation of alpha-actinin alternative splicing by CELF proteins and polypyrimidine tract binding protein. *RNA* **9**, 443–456.

Gu, W., Pan, F., Zhang, H., Bassell, G.J. & Singer, R.H. (2002) A predominantly nuclear protein affecting cytoplasmic localization of beta-actin mRNA in fibroblasts and neurons. *J Cell Biol* **156**, 41–51.

Habelhah, H., Shah, K., Huang, L., Ostareck-Lederer, A., Burlingame, A.L., Shokat, K.M., Hentze, M.W. & Ronai, Z. (2001) ERK

phosphorylation drives cytoplasmic accumulation of hnRNP-K and inhibition of mRNA translation. *Nat Cell Biol* **3**, 325–330.

Halgren, C., Bache, I., Bak, M., Myatt, M.W., Anderson, C.M., Brondum-Nielsen, K. & Tommerup, N. (2012) Haploinsufficiency of CELF4 at 18q12.2 is associated with developmental and behavioral disorders, seizures, eye manifestations, and obesity. *Eur J Human Genet* **20**, 1315–1319.

Hammock, E.A. & Levitt, P. (2011) Developmental expression mapping of a gene implicated in multiple neurodevelopmental disorders, A2bp1 (Fox1). *Dev Neurosci* **33**, 64–74.

Han, S.P., Tang, Y.H. & Smith, R. (2010) Functional diversity of the hnRNPs: past, present and perspectives. *Biochem J* **430**, 379–392.

Hart, A.B., Engelhardt, B.E., Wardle, M.C., Sokoloff, G., Stephens, M., de Wit, H. & Palmer, A.A. (2012) Genome-wide association study of d-amphetamine response in healthy volunteers identifies putative associations, including cadherin 13 (CDH13). *PLoS One* **7**, e42646.

Henneberg, B., Swiniarski, S., Sabine, B. & Illenberger, S. (2010) A conserved peptide motif in Raver2 mediates its interaction with the polypyrimidine tract-binding protein. *Exp Cell Res* **316**, 966–979.

Higgins, G.A. & Fletcher, P.J. (2015) Therapeutic potential of 5-HT2C receptor agonists for addictive disorders. *ACS Chem Neurosci* **6**, 1071–1088.

Higuchi, M., Maas, S., Single, F.N., Hartner, J., Rozov, A., Burnashev, N., Feldmeyer, D., Sprengel, R. & Seeburg, P.H. (2000) Point mutation in an AMPA receptor gene rescues lethality in mice deficient in the RNA-editing enzyme ADAR2. *Nature* **406**, 78–81.

Huelga, S.C., Vu, A.Q., Arnold, J.D., Liang, T.Y., Liu, P.P., Yan, B.Y., Donohue, J.P., Shiue, L., Hoon, S., Brenner, S., Ares, M. Jr. & Yeo, G.W. (2012) Integrative genome-wide analysis reveals cooperative regulation of alternative splicing by hnRNP proteins. *Cell Rep* **1**, 167–178.

Huttelmaier, S., Zenklusen, D., Lederer, M., Dictenberg, J., Lorenz, M., Meng, X., Bassell, G.J., Condeelis, J. & Singer, R.H. (2005) Spatial regulation of beta-actin translation by Src-dependent phosphorylation of ZBP1. *Nature* **438**, 512–515.

Ince-Dunn, G., Okano, H.J., Jensen, K.B., Park, W.Y., Zhong, R., Ule, J., Mele, A., Fak, J.J., Yang, C., Zhang, C., Yoo, J., Herre, M., Okano, H., Noebels, J.L. & Darnell, R.B. (2012) Neuronal Elav-like (Hu) proteins regulate RNA splicing and abundance to control glutamate levels and neuronal excitability. *Neuron* **75**, 1067–1080.

Ivshina, M., Lasko, P. & Richter, J.D. (2014) Cytoplasmic polyadenylation element binding proteins in development, health, and disease. *Annu Rev Cell Dev Biol* **30**, 393–415.

Johnson, M.M., Michelhaugh, S.K., Bouhamdan, M., Schmidt, C.J. & Bannon, M.J. (2011) The transcription factor NURR1 exerts concentration-dependent effects on target genes mediating distinct biological processes. *Front Neurosci* **5**, 135.

Katz, Y., Wang, E.T., Airoldi, E.M. & Burge, C.B. (2010) Analysis and design of RNA sequencing experiments for identifying isoform regulation. *Nat Methods* **7**, 1009–1015.

Kawahara, Y., Grimberg, A., Teegarden, S., Mombereau, C., Liu, S., Bale, T.L., Blendy, J.A. & Nishikura, K. (2008) Dysregulated editing of serotonin 2C receptor mRNAs results in energy dissipation and loss of fat mass. *J Neurosci* **28**, 12834–12844.

Kendler, K.S., Bulik, C.M., Silberg, J., Hettema, J.M., Myers, J. & Prescott, C.A. (2000) Childhood sexual abuse and adult psychiatric and substance use disorders in women: an epidemiological and cotwin control analysis. *Arch Gen Psychiatry* **57**, 953–959.

Keppetipola, N., Sharma, S., Li, Q. & Black, D.L. (2012) Neuronal regulation of pre-mRNA splicing by polypyrimidine tract binding proteins, PTBP1 and PTBP2. *Crit Rev Biochem Mol Biol* **47**, 360–378.

Kim, H.J., Raphael, A.R., LaDow, E.S., McGurk, L., Weber, R.A., Trojanowski, J.Q., Lee, V.M., Finkbeiner, S., Gitler, A.D. & Bonini, N.M. (2014) Therapeutic modulation of eIF2alpha phosphorylation rescues TDP-43 toxicity in amyotrophic lateral sclerosis disease models. *Nat Genet* **46**, 152–160.

Kim, H.H., Lee, S.J., Gardiner, A.S., Perrone-Bizzozero, N.I. & Yoo, S. (2015) Different motif requirements for the localization zipcode element of beta-actin mRNA binding by HuD and ZBP1. *Nucleic Acids Res* **43**, 7432–7446.

King, H.A. & Gerber, A.P. (2014) Translatome profiling: methods for genome-scale analysis of mRNA translation. *Brief Funct Genomics* **30**, 169–175.

Kobori, N., Clifton, G.L. & Dash, P. (2002) Altered expression of novel genes in the cerebral cortex following experimental brain injury. *Brain Res Mol Brain Res* **104**, 148–158.

Kumar, V., Kim, K., Joseph, C., Kourrich, S., Yoo, S.H., Huang, H.C., Vitaterna, M.H., de Villena, F.P., Churchill, G., Bonci, A. & Takahashi, J.S. (2013) C57BL/6N mutation in cytoplasmic FMRP interacting protein 2 regulates cocaine response. *Science* **342**, 1508–1512.

Kuroyanagi, H. (2009) Fox-1 family of RNA-binding proteins. *Cell Mol Life Sci* **66**, 3895–3907.

Ladd, A.N. (2013) CUG-BP, Elav-like family (CELF)-mediated alternative splicing regulation in the brain during health and disease. *Mol Cell Neurosci* **56**, 456–464.

Ladd, A.N. & Cooper, T.A. (2004) Multiple domains control the subcellular localization and activity of ETR-3, a regulator of nuclear and cytoplasmic RNA processing events. *J Cell Sci* **117**, 3519–3529.

Ladd, A.N., Nguyen, N.H., Malhotra, K. & Cooper, T.A. (2004) CELF6, a member of the CELF family of RNA-binding proteins, regulates muscle-specific splicing enhancer-dependent alternative splicing. *J Biol Chem* **279**, 17756–17764.

Lapidus, K.A., Nwokafor, C., Scott, D., Baroni, T.E., Tenenbaum, S.A., Hiroi, N., Singer, R.H. & Czaplinski, K. (2012) Transgenic expression of ZBP1 in neurons suppresses cocaine-associated conditioning. *Learn Mem* **19**, 35–42.

Lau, A.G., Irier, H.A., Gu, J., Tian, D., Ku, L., Liu, G., Xia, M., Fritsch, B., Zheng, J.Q., Dingledine, R., Xu, B., Lu, B. & Feng, Y. (2010) Distinct 3′UTRs differentially regulate activity-dependent translation of brain-derived neurotrophic factor (BDNF). *Proc Natl Acad Sci USA* **107**, 15945–15950.

Leal, G., Afonso, P.M. & Duarte, C.B. (2014) Neuronal activity induces synaptic delivery of hnRNP A2/B1 by a BDNF-dependent mechanism in cultured hippocampal neurons. *PLoS One* **9**, e108175.

Lee, P.T., Chao, P.K., Ou, L.C., Chuang, J.Y., Lin, Y.C., Chen, S.C., Chang, H.F., Law, P.Y., Loh, H.H., Chao, Y.S., Su, T.P. & Yeh, S.H. (2014) Morphine drives internal ribosome entry site-mediated hnRNP K translation in neurons through opioid receptor-dependent signaling. *Nucleic Acids Res* **42**, 13012–13025.

Lein, E.S., Hawrylycz, M.J., Ao, N. *et al.* (2007) Genome-wide atlas of gene expression in the adult mouse brain. *Nature* **445**, 168–176.

Levran, O., Randesi, M., da Rosa, J.C., Ott, J., Rotrosen, J., Adelson, M. & Kreek, M.J. (2015) Overlapping dopaminergic pathway genetic susceptibility to heroin and cocaine addictions in African Americans. *Ann Hum Genet* **79**, 188–198.

Leyton, M. & Vezina, P. (2014) Dopamine ups and downs in vulnerability to addictions: a neurodevelopmental model. *Trends Pharmacol Sci* **35**, 268–276.

Li, J.B. & Church, G.M. (2013) Deciphering the functions and regulation of brain-enriched A-to-I RNA editing. *Nat Neurosci* **16**, 1518–1522.

Li, S.J., Li, Y., Cui, S.C., Qi, Y., Zhao, J.J., Liu, X.Y., Xu, P. & Chen, X.H. (2013) Splicing factor transformer-2beta (Tra2beta) regulates the expression of regulator of G protein signaling 4 (RGS4) gene and is induced by morphine. *PLoS One* **8**, e72220.

Licatalosi, D.D., Yano, M., Fak, J.J., Mele, A., Grabinski, S.E., Zhang, C. & Darnell, R.B. (2012) Ptbp2 represses adult-specific splicing to regulate the generation of neuronal precursors in the embryonic brain. *Genes Dev* **26**, 1626–1642.

Liu, Y. & Szaro, B.G. (2011) hnRNP K post-transcriptionally co-regulates multiple cytoskeletal genes needed for axonogenesis. *Development* **138**, 3079–3090.

Liu, Y., Gervasi, C. & Szaro, B.G. (2008) A crucial role for hnRNP K in axon development in *Xenopus laevis*. *Development* **135**, 3125–3135.

van Loo, K.M. & Martens, G.J. (2007) Genetic and environmental factors in complex neurodevelopmental disorders. *Curr Genomics* **8**, 429–444.

Maloney, S.E., Khangura, E. & Dougherty, J.D. (2015) The RNA-binding protein Celf6 is highly expressed in diencephalic

nuclei and neuromodulatory cell populations of the mouse brain. *Brain Struct Funct*.

Mauger, D.M., Lin, C. & Garcia-Blanco, M.A. (2008) hnRNP H and hnRNP F complex with Fox2 to silence fibroblast growth factor receptor 2 exon IIIc. *Mol Cell Biol* **28**, 5403–5419.

Michalon, A., Sidorov, M., Ballard, T.M., Ozmen, L., Spooren, W., Wettstein, J.G., Jaeschke, G., Bear, M.F. & Lindemann, L. (2012) Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice. *Neuron* **74**, 49–56.

Moraes, K.C., Wilusz, C.J. & Wilusz, J. (2006) CUG-BP binds to RNA substrates and recruits PARN deadenylase. *RNA* **12**, 1084–1091.

Napoli, I., Mercaldo, V., Boyl, P.P., Eleuteri, B., Zalfa, F., De Rubeis, S., Di Marino, D., Mohr, E., Massimi, M., Falconi, M., Witke, W., Costa-Mattioli, M., Sonenberg, N., Achsel, T. & Bagni, C. (2008) The fragile X syndrome protein represses activity-dependent translation through CYFIP1, a new 4E-BP. *Cell* **134**, 1042–1054.

Narayanan, U., Nalavadi, V., Nakamoto, M., Thomas, G., Ceman, S., Bassell, G.J. & Warren, S.T. (2008) S6K1 phosphorylates and regulates fragile X mental retardation protein (FMRP) with the neuronal protein synthesis-dependent mammalian target of rapamycin (mTOR) signaling cascade. *J Biol Chem* **283**, 18478–18482.

Nestler, E.J., Barrot, M. & Self, D.W. (2001) DeltaFosB: a sustained molecular switch for addiction. *Proc Natl Acad Sci USA* **98**, 11042–11046.

Norris, A.D., Gao, S., Norris, M.L., Ray, D., Ramani, A.K., Fraser, A.G., Morris, Q., Hughes, T.R., Zhen, M. & Calarco, J.A. (2014) A pair of RNA-binding proteins controls networks of splicing events contributing to specialization of neural cell types. *Mol Cell* **54**, 946–959.

Okano, H.J. & Darnell, R.B. (1997) A hierarchy of Hu RNA binding proteins in developing and adult neurons. *J Neurosci* **17**, 3024–3037.

Pan, F., Huttelmaier, S., Singer, R.H. & Gu, W. (2007) ZBP2 facilitates binding of ZBP1 to beta-actin mRNA during transcription. *Mol Cell Biol* **27**, 8340–8351.

Park, E., Iaccarino, C., Lee, J., Kwon, I., Baik, S.M., Kim, M., Seong, J.Y., Son, G.H., Borrelli, E. & Kim, K. (2011) Regulatory roles of heterogeneous nuclear ribonucleoprotein M and Nova-1 protein in alternative splicing of dopamine D2 receptor pre-mRNA. *J Biol Chem* **286**, 25301–25308.

Pascale, A., Amadio, M., Caffino, L., Racagni, G., Govoni, S. & Fumagalli, F. (2011) ELAV-GAP43 pathway activation following combined exposure to cocaine and stress. *Psychopharmacology (Berl)* **218**, 249–256.

Perrone-Bizzozero, N. & Bolognani, F. (2002) Role of HuD and other RNA-binding proteins in neural development and plasticity. *J Neurosci Res* **68**, 121–126.

Perycz, M., Urbanska, A.S., Krawczyk, P.S., Parobczak, K. & Jaworski, J. (2011) Zipcode binding protein 1 regulates the development of dendritic arbors in hippocampal neurons. *J Neurosci* **31**, 5271–5285.

Picetti, R., Saiardi, A., Abdel Samad, T., Bozzi, Y., Baik, J.H. & Borrelli, E. (1997) Dopamine D2 receptors in signal transduction and behavior. *Crit Rev Neurobiol* **11**, 121–142.

Pilaz, L.J. & Silver, D.L. (2015) Post-transcriptional regulation in corticogenesis: how RNA-binding proteins help build the brain. *Wiley Interdiscip Rev RNA* **6**, 501–515.

Polydorides, A.D., Okano, H.J., Yang, Y.Y., Stefani, G. & Darnell, R.B. (2000) A brain-enriched polypyrimidine tract-binding protein antagonizes the ability of Nova to regulate neuron-specific alternative splicing. *Proc Natl Acad Sci USA* **97**, 6350–6355.

Ratti, A., Fallini, C., Colombrita, C., Pascale, A., Laforenza, U., Quattrone, A. & Silani, V. (2008) Post-transcriptional regulation of neuro-oncological ventral antigen 1 by the neuronal RNA-binding proteins ELAV. *J Biol Chem* **283**, 7531–7541.

Robinow, S., Campos, A.R., Yao, K.M. & White, K. (1988) The elav gene product of Drosophila, required in neurons, has three RNP consensus motifs. *Science* **242**, 1570–1572.

Romanelli, M.G., Diani, E. & Lievens, P.M. (2013) New insights into functional roles of the polypyrimidine tract-binding protein. *Int J Mol Sci* **14**, 22906–22932.

Romano, M. & Buratti, E. (2013) Targeting RNA binding proteins involved in neurodegeneration. *J Biomol Screen* **18**, 967–983.

Rosenthal, J.J. (2015) The emerging role of RNA editing in plasticity. *J Exp Biol* **218**, 1812–1821.

Ross, A.F., Oleynikov, Y., Kislauskis, E.H., Taneja, K.L. & Singer, R.H. (1997) Characterization of a beta-actin mRNA zipcode-binding protein. *Mol Cell Biol* **17**, 2158–2165.

Russo, S.J., Mazei-Robison, M.S., Ables, J.L. & Nestler, E.J. (2009) Neurotrophic factors and structural plasticity in addiction. *Neuropharmacology* **56** (Suppl 1), 73–82.

Sasabe, T., Futai, E. & Ishiura, S. (2011) Polypyrimidine tract-binding protein 1 regulates the alternative splicing of dopamine receptor D2. *J Neurochem* **116**, 76–81.

Sasaki, Y., Welshhans, K., Wen, Z., Yao, J., Xu, M., Goshima, Y., Zheng, J.Q. & Bassell, G.J. (2010) Phosphorylation of zipcode binding protein 1 is required for brain-derived neurotrophic factor signaling of local beta-actin synthesis and growth cone turning. *J Neurosci* **30**, 9349–9358.

Satterlee, J.S., Basanta-Sanchez, M., Blanco, S., Li, J.B., Meyer, K., Pollock, J., Sadri-Vakili, G. & Rybak-Wolf, A. (2014) Novel RNA modifications in the nervous system: form and function. *J Neurosci* **34**, 15170–15177.

Sawicka, K., Bushell, M., Spriggs, K.A. & Willis, A.E. (2008) Polypyrimidine-tract-binding protein: a multifunctional RNA-binding protein. *Biochem Soc Trans* **36**, 641–647.

Schmidt, H.D., McFarland, K.N., Darnell, S.B., Huizenga, M.N., Sangrey, G.R., Cha, J.H., Pierce, R.C. & Sadri-Vakili, G. (2014) ADAR2-dependent GluA2 editing regulates cocaine seeking. *Mol Psychiatry* **20**, 1460–1466.

Singh, M., Kesterson, R.A., Jacobs, M.M., Joers, J.M., Gore, J.C. & Emeson, R.B. (2007) Hyperphagia-mediated obesity in transgenic mice misexpressing the RNA-editing enzyme ADAR2. *J Biol Chem* **282**, 22448–22459.

Singh, M., Singh, M.M., Na, E., Agassandian, K., Zimmerman, M.B. & Johnson, A.K. (2011) Altered ADAR 2 equilibrium and 5HT(2C) R editing in the prefrontal cortex of ADAR 2 transgenic mice. *Genes Brain Behav* **10**, 637–647.

Sinha, R. (2011) New findings on biological factors predicting addiction relapse vulnerability. *Curr Psychiatry Rep* **13**, 398–405.

Sinnamon, J.R. & Czaplinski, K. (2011) mRNA trafficking and local translation: the Yin and Yang of regulating mRNA localization in neurons. *Acta Biochim Biophys Sin* **43**, 663–670.

Sinnamon, J.R., Waddell, C.B., Nik, S., Chen, E.I. & Czaplinski, K. (2012) Hnrpab regulates neural development and neuron cell survival after glutamate stimulation. *RNA* **18**, 704–719.

Slotkin, W. & Nishikura, K. (2013) Adenosine-to-inosine RNA editing and human disease. *Genome Med* **5**, 105.

Smith, J.W., Fetsko, L.A., Xu, R. & Wang, Y. (2002) Dopamine D2L receptor knockout mice display deficits in positive and negative reinforcing properties of morphine and in avoidance learning. *Neuroscience* **113**, 755–765.

Smith, L.N., Jedynak, J.P., Fontenot, M.R., Hale, C.F., Dietz, K.C., Taniguchi, M., Thomas, F.S., Zirlin, B.C., Birnbaum, S.G., Huber, K.M., Thomas, M.J. & Cowan, C.W. (2014) Fragile X mental retardation protein regulates synaptic and behavioral plasticity to repeated cocaine administration. *Neuron* **82**, 645–658.

Song, K.Y., Choi, H.S., Law, P.Y., Wei, L.N. & Loh, H.H. (2012) Post-transcriptional regulation of mu-opioid receptor: role of the RNA-binding proteins heterogeneous nuclear ribonucleoprotein H1 and F. *Cell Mol Life Sci* **69**, 599–610.

Sora, I., Hall, F.S., Andrews, A.M., Itokawa, M., Li, X.F., Wei, H.B., Wichems, C., Lesch, K.P., Murphy, D.L. & Uhl, G.R. (2001) Molecular mechanisms of cocaine reward: combined dopamine and serotonin transporter knockouts eliminate cocaine place preference. *Proc Natl Acad Sci USA* **98**, 5300–5305.

Spellman, R., Rideau, A., Matlin, A., Gooding, C., Robinson, F., McGlincy, N., Grellscheid, S.N., Southby, J., Wollerton, M. & Smith, C.W. (2005) Regulation of alternative splicing by PTB and associated factors. *Biochem Soc Trans* **33**, 457–460.

Sun, S., Zhang, Z., Fregoso, O. & Krainer, A.R. (2012) Mechanisms of activation and repression by the alternative splicing factors RBFOX1/2. *RNA* **18**, 274–283.

Szumlinski, K.K., Dehoff, M.H., Kang, S.H., Frys, K.A., Lominac, K.D., Klugmann, M., Rohrer, J., Griffin, W. III, Toda, S., Champtiaux, N.P., Berry, T., Tu, J.C., Shealy, S.E., During, M.J., Middaugh, L.D., Worley, P.F. & Kalivas, P.W. (2004) Homer proteins regulate sensitivity to cocaine. *Neuron* **43**, 401–413.

Tang, Y.H., Han, S.P., Kassahn, K.S., Skarshewski, A., Rothnagel, J.A. & Smith, R. (2012) Complex evolutionary relationships among four classes of modular RNA-binding splicing regulators in eukaryotes: the hnRNP, SR, ELAV-like and CELF proteins. *J Mol Evol* **75**, 214–228.

Thomas, M.G., Pascual, M.L., Maschi, D., Luchelli, L. & Boccaccio, G.L. (2014) Synaptic control of local translation: the plot thickens with new characters. *Cell Mol Life Sci* **71**, 2219–2239.

Thyagarajan, A. & Szaro, B.G. (2004) Phylogenetically conserved binding of specific K homology domain proteins to the 3′-untranslated region of the vertebrate middle neurofilament mRNA. *J Biol Chem* **279**, 49680–49688.

Till, S.M. (2010) The developmental roles of FMRP. *Biochem Soc Trans* **38**, 507–510.

Tiruchinapalli, D.M., Oleynikov, Y., Kelic, S., Shenoy, S.M., Hartley, A., Stanton, P.K., Singer, R.H. & Bassell, G.J. (2003) Activity-dependent trafficking and dynamic localization of zipcode binding protein 1 and beta-actin mRNA in dendrites and spines of hippocampal neurons. *J Neurosci* **23**, 3251–3261.

Tiruchinapalli, D.M., Caron, M.G. & Keene, J.D. (2008) Activity-dependent expression of ELAV/Hu RBPs and neuronal mRNAs in seizure and cocaine brain. *J Neurochem* **107**, 1529–1543.

Tolino, M., Kohrmann, M. & Kiebler, M.A. (2012) RNA-binding proteins involved in RNA localization and their implications in neuronal diseases. *Eur J Neurosci* **35**, 1818–1836.

Traynor, J. (2010) Regulator of G protein-signaling proteins and addictive drugs. *Ann N Y Acad Sci* **1187**, 341–352.

Ule, J., Ule, A., Spencer, J., Williams, A., Hu, J.S., Cline, M., Wang, H., Clark, T., Fraser, C., Ruggiu, M., Zeeberg, B.R., Kane, D., Weinstein, J.N., Blume, J. & Darnell, R.B. (2005) Nova regulates brain-specific splicing to shape the synapse. *Nat Genet* **37**, 844–852.

Underwood, J.G., Boutz, P.L., Dougherty, J.D., Stoilov, P. & Black, D.L. (2005) Homologues of the *Caenorhabditis elegans* Fox-1 protein are neuronal splicing regulators in mammals. *Mol Cell Biol* **25**, 10005–10016.

Van Dusen, C.M., Yee, L., McNally, L.M. & McNally, M.T. (2010) A glycine-rich domain of hnRNP H/F promotes nucleocytoplasmic shuttling and nuclear import through an interaction with transportin 1. *Mol Cell Biol* **30**, 2552–2562.

Vanevski, F. & Xu, B. (2015) HuD interacts with Bdnf mRNA and is essential for activity-induced BDNF synthesis in dendrites. *PLoS One* **10**, e0117264.

Volman, S.F., Lammel, S., Margolis, E.B., Kim, Y., Richard, J.M., Roitman, M.F. & Lobo, M.K. (2013) New insights into the specificity and plasticity of reward and aversion encoding in the mesolimbic system. *J Neurosci* **33**, 17569–17576.

Wagnon, J.L., Mahaffey, C.L., Sun, W., Yang, Y., Chao, H.T. & Frankel, W.N. (2011) Etiology of a genetically complex seizure disorder in Celf4 mutant mice. *Genes Brain Behav* **10**, 765–777.

Wagnon, J.L., Briese, M., Sun, W., Mahaffey, C.L., Curk, T., Rot, G., Ule, J. & Frankel, W.N. (2012) CELF4 regulates translation and local abundance of a vast set of mRNAs, including genes associated with regulation of synaptic function. *PLoS Genet* **8**, e1003067.

Wang, H., Wu, L.J., Kim, S.S., Lee, F.J., Gong, B., Toyoda, H., Ren, M., Shang, Y.Z., Xu, H., Liu, F., Zhao, M.G. & Zhuo, M. (2008) FMRP acts as a key messenger for dopamine modulation in the forebrain. *Neuron* **59**, 634–647.

Wang, G.S., Kuyumcu-Martinez, M.N., Sarma, S., Mathur, N., Wehrens, X.H. & Cooper, T.A. (2009) PKC inhibition ameliorates the cardiac phenotype in a mouse model of myotonic dystrophy type 1. *J Clin Invest* **119**, 3797–3806.

Wang, H., Kim, S.S. & Zhuo, M. (2010) Roles of fragile X mental retardation protein in dopaminergic stimulation-induced synapse-associated protein synthesis and subsequent alpha-amino-3-hydroxyl-5-methyl-4-isoxazole-4-propionate (AMPA) receptor internalization. *J Biol Chem* **285**, 21888–21901.

Wang, J., Yuan, W. & Li, M.D. (2011) Genes and pathways co-associated with the exposure to multiple drugs of abuse, including alcohol, amphetamine/methamphetamine, cocaine, marijuana, morphine, and/or nicotine: a review of proteomics analyses. *Mol Neurobiol* **44**, 269–286.

Wang, Y., Ma, M., Xiao, X. & Wang, Z. (2012) Intronic splicing enhancers, cognate splicing factors and context-dependent regulation rules. *Nat Struct Mol Biol* **19**, 1044–1052.

Watanabe, Y., Yoshimoto, K., Tatebe, H., Kita, M., Nishikura, K., Kimura, M. & Tanaka, M. (2014) Enhancement of alcohol drinking in mice depends on alterations in RNA editing of serotonin 2C receptors. *Int J Neuropsychopharmacol* **17**, 739–751.

Welshhans, K. & Bassell, G.J. (2011) Netrin-1-induced local beta-actin synthesis and growth cone guidance requires zipcode binding protein 1. *J Neurosci* **31**, 9800–9813.

Welter, D., MacArthur, J., Morales, J., Burdett, T., Hall, P., Junkins, H., Klemm, A., Flicek, P., Manolio, T., Hindorff, L. & Parkinson, H. (2014) The NHGRI GWAS Catalog, a curated resource of SNP-trait associations. *Nucleic Acids Res* **42**, D1001–D1006.

Wermter, A.K., Laucht, M., Schimmelmann, B.G., Banaschewski, T., Sonuga-Barke, E.J., Rietschel, M. & Becker, K. (2010) From nature versus nurture, via nature and nurture, to gene x environment interaction in mental disorders. *Eur Child Adolesc Psychiatry* **19**, 199–210.

Werry, T.D., Loiacono, R., Sexton, P.M. & Christopoulos, A. (2008) RNA editing of the serotonin 5HT2C receptor and its effects on cell signalling, pharmacology and brain function. *Pharmacol Ther* **119**, 7–23.

Weyn-Vanhentenryck, S.M., Mele, A., Yan, Q., Sun, S., Farny, N., Zhang, Z., Xue, C., Herre, M., Silver, P.A., Zhang, M.Q., Krainer, A.R., Darnell, R.B. & Zhang, C. (2014) HITS-CLIP and integrative modeling define the Rbfox splicing-regulatory network linked to brain development and autism. *Cell Rep* **6**, 1139–1152.

Xie, J., Lee, J.A., Kress, T.L., Mowry, K.L. & Black, D.L. (2003) Protein kinase A phosphorylation modulates transport of the polypyrimidine tract-binding protein. *Proc Natl Acad Sci USA* **100**, 8776–8781.

Xu, J., Lu, Z., Xu, M., Pan, L., Deng, Y., Xie, X., Liu, H., Ding, S., Hurd, Y.L., Pasternak, G.W., Klein, R.J., Cartegni, L., Zhou, W. & Pan, Y.X. (2014) A heroin addiction severity-associated intronic single nucleotide polymorphism modulates alternative pre-mRNA splicing of the mu opioid receptor gene OPRM1 via hnRNPH interactions. *J Neurosci* **34**, 11048–11066.

Yang, Y., Mahaffey, C.L., Berube, N., Maddatu, T.P., Cox, G.A. & Frankel, W.N. (2007) Complex seizure disorder caused by Brunol4 deficiency in mice. *PLoS Genet* **3**, e124.

Yano, M., Okano, H.J. & Okano, H. (2005) Involvement of Hu and heterogeneous nuclear ribonucleoprotein K in neuronal differentiation through p21 mRNA post-transcriptional regulation. *J Biol Chem* **280**, 12690–12699.

Yazdani, N., Parker, C.C., Shen, Y., Reed, E.R., Guido, M.A., Kole, L.A., Kirkpatrick, S.L., Lim, J.E., Sokoloff, G., Cheng, R., Johnson, W.E., Palmer, A.A. & Bryant, C.D. (2015) *Hnrnph1* is a quantitative trait gene for methamphetamine sensitivity. Accepted, *PLOS Genetics*.

Yeo, G.W., Coufal, N.G., Liang, T.Y., Peng, G.E., Fu, X.D. & Gage, F.H. (2009) An RNA code for the FOX2 splicing regulator revealed by mapping RNA-protein interactions in stem cells. *Nat Struct Mol Biol* **16**, 130–137.

Yoo, S., Kim, H.H., Kim, P., Donnelly, C.J., Kalinski, A.L., Vuppalanchi, D., Park, M., Lee, S.J., Merianda, T.T., Perrone-Bizzozero, N.I. & Twiss, J.L. (2013) A HuD-ZBP1 ribonucleoprotein complex localizes GAP-43 mRNA into axons through its 3′ untranslated region AU-rich regulatory element. *J Neurochem* **126**, 792–804.

Yoon, Y., McKenna, M.C., Rollins, D.A., Song, M., Nuriel, T., Gross, S.S., Xu, G. & Glatt, C.E. (2013) Anxiety-associated alternative polyadenylation of the serotonin transporter mRNA confers translational regulation by hnRNPK. *Proc Natl Acad Sci USA* **110**, 11624–11629.

Zaniewska, M., McCreary, A.C., Wydra, K. & Filip, M. (2010) Effects of serotonin (5-HT)2 receptor ligands on depression-like behavior during nicotine withdrawal. *Neuropharmacology* **58**, 1140–1146.

Zaniewska, M., Alenina, N., Wydra, K., Frohler, S., Kusmider, M., McCreary, A.C., Chen, W., Bader, M. & Filip, M. (2015) Discovering the mechanisms underlying serotonin (5-HT)2A and 5-HT2C receptor regulation following nicotine withdrawal in rats. *J Neurochem* **134**, 704–716.

Zhang, H.L., Eom, T., Oleynikov, Y., Shenoy, S.M., Liebelt, D.A., Dictenberg, J.B., Singer, R.H. & Bassell, G.J. (2001) Neurotrophin-induced transport of a beta-actin mRNP complex increases beta-actin levels and stimulates growth cone motility. *Neuron* **31**, 261–275.

Zhang, C., Zhang, Z., Castle, J., Sun, S., Johnson, J., Krainer, A.R. & Zhang, M.Q. (2008) Defining the regulatory network of the tissue-specific splicing factors Fox-1 and Fox-2. *Genes Dev* **22**, 2550–2563.

Zhang, G., Neubert, T.A. & Jordan, B.A. (2012) RNA binding proteins accumulate at the postsynaptic density with synaptic activity. *J Neurosci* **32**, 599–609.

Zheng, S., Gray, E.E., Chawla, G., Porse, B.T., O'Dell, T.J. & Black, D.L. (2012) PSD-95 is post-transcriptionally repressed during early neural development by PTBP1 and PTBP2. *Nat Neurosci* **15**, 381–388, S1.

Zhong, X., Drgonova, J., Li, C.Y. & Uhl, G.R. (2015) Human cell adhesion molecules: annotated functional subtypes and overrepresentation of addiction-associated genes. *Ann N Y Acad Sci* **1349**, 83–95.

## Acknowledgments